


BENZAMIDE AND HETEROARENE DERIVATIVES

The present invention relates to novel benzamide and heteroarene carboxamide derivatives, processes for their preparation, their use as pharmaceuticals and to pharmaceutical compositions comprising them.


More particularly, there is provided in a first aspect a compound of formula I



wherein

R¹ is C₁-C₆alkyl, halo-C₁-C₆alkyl, halo-C₁-C₆alkoxy, C₃-C₈cycloalkyl, halo-C₃-C₈cycloalkyl or tri-C₁-C₆alkylsilyl;

R² is hydrogen or a group



wherein

R⁶ and R⁷ are independently hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy;

R⁸ and R⁹ are independently hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy;

X is CR¹² or N;

Y is CH or N;

wherein X and Y are not N at the same time;

R¹² is hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy;

- R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
- R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;
- 5 A is CR^{10} or N;
 B is CR^{11} or N;
 D is CR^3 or N;
- wherein $-B=A-$ and $-A=D-$ are not $-N=N-$;
- R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 -
10 alkoxy;
- R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;
- R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;
- 15 wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;
 and
 n is 1, 2 or 3;
 and pharmaceutically acceptable salts thereof.

Examples of C_1 - C_6 alkyl include branched and straight-chain monovalent saturated
20 aliphatic hydrocarbon radicals of one to six carbon atoms, e.g. methyl, ethyl, propyl,
 isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls and the isomeric hexyls.

Examples of halogen include fluorine, chlorine, bromine and iodine.

Examples of halo- C_1 - C_6 alkyl include C_1 - C_6 alkyl groups as defined above wherein at least
one of the hydrogen atoms of the C_1 - C_6 alkyl group is replaced by a halogen atom, e.g.
25 fluoro or chloro, e.g. trifluoromethyl, difluoromethyl, fluoromethyl, 1,2,2,2-tetrafluoro-1-
 trifluoromethyl-ethyl, pentafluoroethyl and chlorodifluoromethyl.

Examples of halo- C_1 - C_6 alkoxy include alkoxy groups of formula $O-C_1$ - C_6 alkyl wherein at
least one of the hydrogen atoms of the alkoxy group is replaced by a halogen atom, e.g.
fluoro or chloro, e.g. trifluoromethoxy, difluoromethoxy, fluoromethoxy and chloro-
30 difluoromethoxy.

Examples of C₃-C₈cycloalkyl include saturated carbocyclic groups containing from 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

Examples of halo-C₃-C₈cycloalkyl include 1-fluorocyclobutyl.

5 Examples of tri-C₁-C₆alkylsilyl include trimethylsilyl.

The term "pharmaceutically acceptable salts" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, preferably hydro-
10 chloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, salicylic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine and the like. In addition these salts may be prepared from addition of an inorganic base or an organic base
15 to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethyl-
20 amine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins and the like. The compound of formula I can also be present in the form of zwitterions. Particularly preferred pharmaceutically acceptable salts of compounds of formula I are the hydrochloride salts.

The compounds of formula I can also be solvated, e.g. hydrated. The solvation can be
25 effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I (hydration). The term pharmaceutically acceptable salts also includes physiologically acceptable solvates.

"Isomers" are compounds that have identical molecular formulae but that differ in the
30 nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereo-

isomers", and stereoisomers that are non-superimposable mirror images are termed "enantiomers", or sometimes optical isomers. A carbon atom bonded to four nonidentical substituents is termed a "chiral center".

In one embodiment the present invention provides a compound of formula I wherein R¹ is C₁-C₆alkyl, halo-C₁-C₆alkyl, C₃-C₈cycloalkyl, halo-C₃-C₈cycloalkyl or tri-C₁-C₆alkylsilyl. In another embodiment the present invention provides a compound of formula I wherein R¹ is C₁-C₆alkyl. In still another embodiment the present invention provides a compound of formula I wherein R¹ is butyl. In still another embodiment the present invention provides a compound of formula I wherein R¹ is tert-butyl.

10 In one embodiment the present invention provides a compound of formula I wherein R² is hydrogen.

In another embodiment the present invention provides a compound of formula I wherein R² is a group (a). In another embodiment the present invention provides a compound of formula I wherein R² is a group (a) wherein R⁶ and R⁷ are independently halo-C₁-C₆alkyl or halogen. In still another embodiment the present invention provides a compound of formula I wherein R² is a group (a) wherein R⁶ halo-C₁-C₆alkyl and R⁷ is halogen. In still another embodiment the present invention provides a compound of formula I wherein R² is a group (a) wherein R⁶ is CF₃ and R⁷ is Cl.

In another embodiment the present invention provides a compound of formula I wherein R² is a group (b). In another embodiment the present invention provides a compound of formula I wherein R² is a group (b) wherein R⁸ and R⁹ are independently hydrogen, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl or halo-C₁-C₆alkoxy. In still another embodiment the present invention provides a compound of formula I wherein R² is a group (b) wherein R⁸ and R⁹ are independently hydrogen, CF₃, Cl, F, cyclopropyl or OCF₃. In still another embodiment the present invention provides a compound of formula I wherein R² is a group (b) wherein R⁸ is hydrogen, CF₃, Cl, F, cyclopropyl or OCF₃. In another embodiment the present invention provides a compound of formula I wherein R² is a group (b) wherein R⁸ and R⁹ are independently hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl or halo-C₁-C₆alkoxy. In still another embodiment the present invention provides a compound of formula I wherein R² is a group (b) wherein R⁸ and R⁹ are independently hydrogen, CH₂CH₃, (CH₂)₂CH₃, CH(CH₃)₂, CF₃, Br, Cl, F, cyclopropyl or OCF₃. In still another embodiment the present invention provides a compound of formula I wherein R² is a group (b) wherein R⁸ is hydrogen, CH₂CH₃, (CH₂)₂CH₃, CH(CH₃)₂, CF₃, Br, Cl, F, cyclo-

propyl or OCF_3 . In still another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein R^9 is hydrogen, Cl or F. In still another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein R^9 is hydrogen or F.

- 5 In another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein X is CR^{12} . In still another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein X is CR^{12} wherein R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen or halo- C_1 - C_6 alkoxy. In still another embodiment the present invention provides a compound of formula I wherein R^2 is a group
- 10 (b) wherein X is CR^{12} wherein R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl or halogen. In still another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein X is CR^{12} wherein R^{12} is hydrogen or halogen. In still another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein X is CR^{12} wherein R^{12} is hydrogen, Cl or F. In still another embodiment
- 15 the present invention provides a compound of formula I wherein R^2 is a group (b) wherein X is CR^{12} wherein R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl or halo- C_1 - C_6 alkoxy. In still another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein X is CR^{12} wherein R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen or C_3 - C_8 cycloalkyl. In still another embodiment the
- 20 present invention provides a compound of formula I wherein R^2 is a group (b) wherein X is CR^{12} wherein R^{12} is hydrogen, halogen or C_3 - C_8 cycloalkyl. In still another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein X is CR^{12} wherein R^{12} is hydrogen, Cl, F or cyclopropyl.

- In another embodiment the present invention provides a compound of formula I wherein
- 25 R^2 is a group (b) wherein X is O or N and Y is CH.

In another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein Y is CH.

In another embodiment the present invention provides a compound of formula I wherein R^2 is a group (b) wherein Y is N and X is CR^{12} .

- 30 In another embodiment the present invention provides a compound of formula I wherein A is CR^{10} . In still another embodiment the present invention provides a compound of formula I wherein A is CR^{10} wherein R^{10} is hydrogen, or is halo- C_1 - C_6 alkyl, halogen,

C₃-C₈cycloalkyl or OH, when at least one of R³, R⁴, R⁵ and R¹¹ is not hydrogen. In still another embodiment the present invention provides a compound of formula I wherein A is CR¹⁰ wherein R¹⁰ is halo-C₁-C₆alkyl or halogen, when at least one of R³, R⁴, R⁵ and R¹¹ is not hydrogen. In still another embodiment the present invention provides a compound of
5 formula I wherein A is CR¹⁰ wherein R¹⁰ is CF₃ or Cl, when at least one of R³, R⁴, R⁵ and R¹¹ is not hydrogen.

In another embodiment the present invention provides a compound of formula I wherein A is N and B and D are not N.

In another embodiment the present invention provides a compound of formula I wherein
10 B is CR¹¹. In another embodiment the present invention provides a compound of formula I wherein B is CR¹¹ wherein R¹¹ is hydrogen or is halogen, when at least two of R³, R⁴, R⁵ and R¹⁰ are not hydrogen. In another embodiment the present invention provides a compound of formula I wherein B is CR¹¹ wherein R¹¹ is hydrogen or is F or Cl, when at least two of R³, R⁴, R⁵ and R¹⁰ are not hydrogen. In still another embodiment the present inven-
15 tion provides a compound of formula I wherein B is CR¹¹ wherein R¹¹ is hydrogen.

In another embodiment the present invention provides a compound of formula I wherein B is N and A is not N.

In another embodiment the present invention provides a compound of formula I wherein D is CR³. In still another embodiment the present invention provides a compound of
20 formula I wherein D is CR³ wherein R³ is hydrogen.

In another embodiment the present invention provides a compound of formula I wherein D is N.

In another embodiment the present invention provides a compound of formula I wherein R⁵ is hydrogen, halo-C₁-C₆alkyl, halogen or OH. In still another embodiment the present
25 invention provides a compound of formula I wherein R⁵ is hydrogen, halo-C₁-C₆alkyl or halogen. In still another embodiment the present invention provides a compound of formula I wherein R⁵ is hydrogen or halogen. In still another embodiment the present invention provides a compound of formula I wherein R⁵ is hydrogen or F.

In another embodiment the present invention provides a compound of formula I wherein
30 R⁴ is hydrogen, or is C₁-C₆alkyl, halo-C₁-C₆alkyl or halogen when at least one of R³, R⁵, R¹⁰ and R¹¹ is not hydrogen. In still another embodiment the present invention provides a

compound of formula I wherein R^4 is halo- C_1 - C_6 alkyl or halogen and at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen. In still another embodiment the present invention provides a compound of formula I wherein R^4 is CF_3 or Cl and at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen. In still another embodiment the present invention provides a compound of

5 formula I wherein R^4 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl or halogen and at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen. In still another embodiment the present invention provides a compound of formula I wherein R^4 is CH_2CH_3 , CF_3 or Cl and at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen.

The present invention provides compounds of formula I wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen.

10

In another embodiment the present invention provides a compound of formula I wherein n is 1.

In one embodiment the present invention provides a compound of formula I wherein

R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cyclo-

15 alkyl or tri- C_1 - C_6 alkylsilyl;

R^2 is hydrogen;

R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo-

20 C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;

A is CR^{10} or N;

B is CR^{11} or N;

D is CR^3 or N;

wherein $-B=A-$ and $-A=D-$ are not $-N=N-$;

25 R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;

R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo-

30 C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;

wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;


and

n is 1, 2 or 3;

and pharmaceutically acceptable salts thereof.

In one embodiment the present invention provides a compound of formula I wherein
 R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl;

R^2 is a group



wherein R^6 and R^7 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

10 R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;

A is CR^{10} or N;

B is CR^{11} or N;

D is CR^3 or N;

15 wherein $-B=A-$ and $-A=D-$ are not $-N=N-$;

R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;

20 R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;

wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;

and


n is 1, 2 or 3;

25 and pharmaceutically acceptable salts thereof.

In one embodiment the present invention provides a compound of formula I wherein

R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl;

R^2 is a group



(b)

wherein

R^8 and R^9 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 -cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

5 X is CR^{12} or N;

Y is CH or N;

wherein X and Y are not N at the same time;

R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

10 R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;

A is CR^{10} or N;

15 B is CR^{11} or N;

D is CR^3 or N;

wherein -B=A- and -A=D- are not -N=N-;

R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

20 R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;

R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;

wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;

25 and


n is 1, 2 or 3;

and pharmaceutically acceptable salts thereof.

In one embodiment the present invention provides a compound of formula I wherein

30 R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl;

R^2 is hydrogen or a group



wherein

R^6 and R^7 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 -cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

5 R^8 and R^9 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 -cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

X is CR^{12} or N;

Y is CH or N;

wherein X and Y are not N at the same time;

10 R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;

15 A is CR^{10} ;

B is CR^{11} or N;

D is CR^3 or N;

R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

20 R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;

R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;

25 wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;

and


n is 1, 2 or 3;

and pharmaceutically acceptable salts thereof.

In one embodiment the present invention provides a compound of formula I wherein

30 R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl;

R² is hydrogen or a group



wherein

R⁶ and R⁷ are independently hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈-cycloalkyl, OH or halo-C₁-C₆alkoxy;

R⁸ and R⁹ are independently hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈-cycloalkyl, OH or halo-C₁-C₆alkoxy;

X is CR¹² or N;

Y is CH or N;

wherein X and Y are not N at the same time;

R¹² is hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy;

R⁵ is hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy;

R⁴ is hydrogen, or is C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy when at least one of R³, R⁵ and R¹¹ is not hydrogen;

A is N;

B is CR¹¹;

D is CR³;

R³ is hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy;

R¹¹ is hydrogen or is C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy, when at least two of R³, R⁴, R⁵ and R¹⁰ are not hydrogen;

wherein at least two of R³, R⁴, R⁵, R¹⁰ and R¹¹ are not hydrogen;

and


n is 1, 2 or 3;

and pharmaceutically acceptable salts thereof.

In one embodiment the present invention provides a compound of formula I wherein

R¹ is C₁-C₆alkyl, halo-C₁-C₆alkyl, halo-C₁-C₆alkoxy, C₃-C₈cycloalkyl, halo-C₃-C₈cycloalkyl or tri-C₁-C₆alkylsilyl;

R² is hydrogen or a group



wherein

R^6 and R^7 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 -cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

5 R^8 and R^9 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 -cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

X is CR^{12} or N;

Y is CH or N;

wherein X and Y are not N at the same time;

10 R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;

A is CR^{10} ;

B is CR^{11} or N;

D is CR^3 ;

20 R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;

R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;

25 wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;

and


n is 1, 2 or 3;

and pharmaceutically acceptable salts thereof.

In one embodiment the present invention provides a compound of formula I wherein

30 R^1 is C_1 - C_6 alkyl;

R^2 is a group



(b)

wherein

R^8 and R^9 are independently hydrogen, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl or halo- C_1 - C_6 alkoxy;

5 X is CR^{12} ;

Y is CH;

R^{12} is hydrogen or halogen;

R^5 is hydrogen or halogen;

R^4 is halo- C_1 - C_6 alkyl or halogen;

10 A is CR^{10} ;

B is CR^{11} or N;

D is CR^3 ;

R^3 is hydrogen;

R^{10} is halo- C_1 - C_6 alkyl or halogen;

15 R^{11} is hydrogen;

and


n is 1, 2 or 3;

and pharmaceutically acceptable salts thereof.

In one embodiment the present invention provides a compound of formula I wherein

20 R^1 is C_1 - C_6 alkyl;

R^2 is a group



(b)

wherein

R^8 and R^9 are independently hydrogen, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl or halo- C_1 - C_6 alkoxy;

25 X is CR^{12} ;


Y is CH;

R^{12} is hydrogen, halogen or C_3 - C_8 cycloalkyl;

R^5 is hydrogen or halogen;


- R^4 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl or halogen;
 A is CR^{10} ;
 B is CR^{11} or N;
 D is CR^3 ;
 5 R^3 is hydrogen;
 R^{10} is halo- C_1 - C_6 alkyl or halogen;
 R^{11} is hydrogen;
 and
 n is 1, 2 or 3;
 10 and pharmaceutically acceptable salts thereof.

In addition, there is provided in a second aspect a process for the production of a compound of formula I



wherein

- 15 R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl;
 R^2 is hydrogen or a group



wherein

- 20 R^6 and R^7 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
 R^8 and R^9 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
 X is CR^{12} or N;
 25 Y is CH or N;

wherein X and Y are not N at the same time;

R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^3 and R^5 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 -
5 C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;

A is CR^{10} or N;

B is CR^{11} or N;

10 D is CR^3 or N;

wherein $-B=A-$ and $-A=D-$ are not $-N=N-$;

R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;


R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo-
15 C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;

wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;

and


n is 1, 2 or 3;

which process comprises reacting an acid derivative, a compound of formula II



wherein R^4 , R^5 , A, B and D have the above meanings and W is hydroxy, OLi, ONa, OK or halogen, e.g. Cl,

with a secondary amine derivative, a compound of formula III



25 wherein R^1 , R^2 and n have the above meanings.

If carboxylic acids ($W=OH$) or carboxylate salts ($W=OLi$, ONa , OK) of formula II are used in this process, standard peptide coupling reagents can be applied to activate the acid prior to the coupling reaction. Typically, the acid derivative II ($R=OH$, OLi , ONa , OK) is mixed

with a coupling reagent such as EDC or EDC·HCl, DCC, HBTU or TBTU in an inert solvent such as N,N-dimethylformamide, dimethylacetamide (DMA) or dichloromethane (DCM) together with the appropriate secondary amine derivative III. Optionally a base (e.g. *N,N*-diisopropylethyl amine, triethylamine, *N*-methyl morpholine) and/or 1-hydroxybenzotriazole (HOBt) can be added. The reaction mixture is stirred for 1 to 24 h at a temperature of about -30°C to about 70°C (e.g. ambient temperature).

Alternatively, acid chlorides (W=Cl) can be reacted with secondary amine derivatives III to obtain formula (I) compounds, using standard protocols.

Acid derivatives of formula II are commercially available or can be prepared as described in the example section.

Secondary amines of the general formula III can be synthesized by standard methods. They may be synthesized as outlined below.


Compounds of formula III



wherein

R^1 is C₁-C₆alkyl, halo-C₁-C₆alkyl, halo-C₁-C₆alkoxy, C₃-C₈cycloalkyl, halo-C₃-C₈cycloalkyl or tri-C₁-C₆alkylsilyl;

R^2 is hydrogen or a group



wherein

R^6 and R^7 are independently hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy;

R^8 and R^9 are independently hydrogen, C₁-C₆alkyl, halo-C₁-C₆alkyl, halogen, C₃-C₈cycloalkyl, OH or halo-C₁-C₆alkoxy;

X is CR¹² or N;

Y is CH or N;

wherein X and Y are not N at the same time;

R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy; and


n is 1, 2 or 3;

- 5 may be prepared by reductive amination of a benzaldehyde derivative, a compound of formula IV



wherein R^1 is as defined above,

with an amine, a compound of formula V



wherein R^2 and n are as defined above.


The necessary starting amines and aldehydes are commercially available or are synthesized using standard methods as e.g. described in the example section.

- 15 Secondary amines III may alternatively be synthesized from amide derivatives, compounds of formula VII



wherein R^1 , R^2 and n are as defined above.

Amide derivatives, compounds of formula VII are available by the coupling of benzoic acid derivatives, compounds of formula VI



wherein R¹ is as defined above,
with a compound of formula V.

There is provided in a third aspect pharmaceutical compositions comprising a compound as defined above as well as a pharmaceutically acceptable carrier and/or adjuvant.

There is provided in a fourth aspect compounds as defined above for use as therapeutically active substances.

There is provided in a fifth aspect a use of compounds as defined above for the preparation of a medicament for the treatment and/or prophylaxis of diseases which are mediated by CETP.

The necessary starting benzoic acids are commercially available or may be synthesized using standard methods as e.g. described in the example section.

The following abbreviations are used: RT: room temperature; THF: tetrahydrofuran; DMF: N,N-dimethylformamide; DCM: dichloromethane

In general, the nomenclature used in this Application is based on AUTONOMTM v.4.0, a Beilstein Institute computerized system for the generation of IUPAC systematic nomenclature.

Aldehydes (Acids) (Compounds of formula IV and VI):

Example S1-A: Preparation of 4-cyclopropyl benzaldehyde:

To a solution of 1-bromo-4-cyclopropylbenzene [synthesized in analogy to a procedure described in J.Org.Chem. 1976, 41, 2262-2266] (1.58 g, 8.04 mmol) in THF at -78°C was added n-BuLi (5.08 ml, 1.6M solution in hexane, 8.11 mmol) and the reaction mixture was stirred at -78°C for 10 min. DMF (1.25 ml, 16.08 mmol) was then added and the reaction mixture was stirred at -78°C for 15 min. The reaction mixture was then warmed to 0°C slowly (over 2h) and stirred at 0°C for 1h. The reaction was quenched with sat. NH₄Cl_(aq) solution and the aqueous phase was extracted with ether. The organic layer was washed with brine, dried (MgSO₄), filtered and concentrated in *vacuo* to give a residue which was purified by flash column chromatography (1:9 diethyl ether/pentane) to give 4-cyclopropyl benzaldehyde (1.10 g, 94%) as a colourless oil. ¹H NMR (CDCl₃, 300 MHz): δ 9.94 (s, 1H), 7.76 (d, J=8.5 Hz, 2H), 7.19 (d, J=8.5 Hz, 2H), 1.97 (m, 1H), 1.13-1.06 (m, 2H), 0.84-0.78 (m, 2H).

Example S2-A: Preparation of 4-cyclobutyl benzaldehyde:

a) Preparation of 1-(4-bromophenyl)-cyclobutanol:

To a solution of 1, 4-dibromobenzene (1.00 g, 4.24 mmol) at -78°C in ether (20 ml) was added *n*-BuLi (2.65 ml, 1.6 M solution in hexane, 4.24 mmol) and the reaction mixture was stirred at -78°C for 30 min. Cyclobutanone (348 μ l, 4.66 mmol) was then added and the reaction mixture was stirred at -78°C for 15 min. The reaction mixture was then slowly (over 2h) warmed to 0°C. and stirred for a further 1h. Water was added followed by sat.

NH₄Cl and the reaction mixture was extracted with ether. The organic layer was washed with brine, dried (MgSO₄), filtered and concentrated in *vacuo* to give a residue which was purified by flash column chromatography (1:4 ether/pentane) to give 1-(4-bromophenyl)-cyclobutanol (330 mg, 34%) as a colourless oil. ¹H NMR (CDCl₃, 300 MHz): δ 7.50 (d, J=8.5 Hz, 2H), 7.38 (d, J=8.5 Hz, 2H), 2.57-2.48 (m, 2H), 2.41-2.31 (m, 2H), 2.02 (m, 1H), 1.69 (m, 1H).

b) Preparation of 1-bromo-4-cyclobutyl-benzene:

To a solution of 1.37 g of 1-(4-bromophenyl)-cyclobutanol (6 mmol) in 15 ml DCM were added 1.15 ml of triethylsilane (7.2 mmol) and the mixture was cooled to -78°C. Then 1.15 ml of boron trifluoride diethyl etherate complex were added and the reaction mixture was warmed to -40°C and stirred for 8 h. The reaction was then quenched by addition of 10% aqueous KHCO₃ and the mixture was extracted three times with DCM. The combined extracts were washed with brine, dried with magnesium sulfate and concentrated. The remaining residue was purified by column chromatography (silica gel; cyclohexane) to give 0.84 g (66%) of 1-bromo-4-cyclobutyl-benzene as a colorless liquid. ¹H NMR (CDCl₃, 300 MHz): δ 1.85 (m, 1H), 1.92-2.18 (m, 3H), 2.33 (m, 2H), 3.49 (quint, J=8.5 Hz, 1H), 7.08 (d, J=8.5 Hz, 2H), 7.40 (d, J=8.5 Hz, 2H).

c) Preparation of 4-cyclobutyl-benzaldehyde:

The title compound was synthesized in analogy to 4-cyclopropyl benzaldehyde (described in example S1-A) using 830 mg of 1-bromo-4-cyclobutyl-benzene (3.93 mmol), 2.7 ml of a 1.6 molar solution of n-BuLi in hexane (4.32 mmol) and 605 µl of DMF (7.86 mmol). The isolated residue was purified by flash column chromatography (5:95 EtOAc/cyclohexane) to give 422 mg of 4-cyclobutyl-benzaldehyde (67%) as a colourless liquid. ¹H NMR (CDCl₃, 300 MHz): δ 1.89 (m, 1H), 1.97-2.26 (m, 3H), 2.40 (m, 2H), 3.63 (quint, J=8.5 Hz, 1H), 7.36 (d, J=8.0 Hz, 2H), 7.81 (d, J=8.0 Hz, 2H), 9.97 (s, 1H).

Example S3-A: Preparation of 4-(1-fluoro-cyclobutyl)-benzaldehyde:

a) Preparation of 1-bromo-4-(1-fluoro-cyclobutyl)-benzene:

To a solution of 5.66 g of 1-(4-bromophenyl)-cyclobutanol (24.92 mmol, described in example S2-A) in 70 ml DCM were added 4.23 g of (diethylamino)sulfur trifluoride (95%, 24.92 mmol) at 0°C. The reaction mixture was stirred at 0°C for 35 min, then sat. NaHCO₃- solution was added and the resulting mixture was extracted with DCM. The combined organic extracts were washed with brine, dried (MgSO₄), filtered, and con-

centrated in *vacuo* to give a residue which was purified by flash column chromatography (100% pentane) to give 1-bromo-4-(1-fluoro-cyclobutyl)-benzene (3.66 g, 64%) as a colourless liquid.

b) Preparation of 4-(1-fluoro-cyclobutyl)-benzaldehyde:

- 5 The title compound was synthesized in analogy to 4-cyclopropyl benzaldehyde (described in example S1-A) using 1.64 g of 1-bromo-4-(1-fluoro-cyclobutyl)-benzene (7.16 mmol), 4.92 ml of a 1.6 molar solution of *n*-BuLi in hexane (7.87 mmol) and 1.1 ml of DMF (14.32 mmol). 4-(1-Fluoro-cyclobutyl)-benzaldehyde was isolated as crude product as a light yellow liquid (1.23 g, 96%). ¹H NMR (CDCl₃, 300 MHz): δ 1.84 (m, 1H), 2.15 (m, 1H),
10 2.49-2.81 (m, 5H), 7.63 (d, J=8 Hz, 2H), 7.92 (d, J=8 Hz, 2H), 10.03 (s, 1H).

Example S4-A: Preparation of 4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-benzaldehyde

- A solution of 3.5 g of 4-(heptafluoroisopropyl)-toluene (13.4 mmol) in 100 ml tetra-chloromethane was heated to reflux. Then 2.63 g of N-bromosuccinimide (14.8 mmol) and
15 326 mg of dibenzoyl peroxide (1.34 mmol) were added in small portions. After 5 h the mixture was cooled to 0°C, filtered and the solvent was evaporated. The remaining residue was dissolved in 15 ml ethanol and was added to a suspension that had been prepared by addition of 2-nitropropane (1.4 ml, 15.5 mmol) to a solution of 340 mg sodium (14.8 mmol) in ethanol. This mixture was stirred for 3 days. Then it was filtered, the solvent was
20 removed and the remaining residue was dissolved in EtOAc and washed with 1 N sodium hydroxide solution, 1 N HCl solution, saturated NaHCO₃ solution and with brine. The EtOAc layer was then dried with magnesium sulfate, filtered and concentrated. Purification of the residue (silica gel; *c*-hexane/EtOAc 10:1) gave 1.1 g (30%) of 4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-benzaldehyde as a light yellow oil. ¹H-NMR (CDCl₃, 300 MHz): δ
25 7.82 (d, J=8 Hz, 2H), 8.03 (d, J=8 Hz, 2H), 10.11 (s, 1H).

Example S5-A: Preparation of 4-pentafluoroethyl-benzoic acid

a) Preparation of 4-pentafluoroethyl-benzonitrile:

- A mixture of 4-iodobenzonitrile (10.0 g, 43.7 mmol), sodium pentafluoropropionate (15.4 g, 82.9 mmol), and copper(I) iodide (16.6 g, 87.3 mmol), DMF (160 mL), and
30 toluene (60 mL) was heated at 160°C for 16 h, allowing most of the toluene to distil off. After cooling, ethyl acetate (200 mL) was added, and the mixture was filtered through diatomaceous earth, and the filtrate was partitioned between ethyl acetate/heptane and

water. The organic layer was washed with brine, dried (MgSO_4), and evaporated. Chromatography (SiO_2 , heptane-ethyl acetate gradient) afforded the title compound (5.05 g 52%). Yellow oil, MS (EI) 221.1 (M^+).

b) Preparation of 4-pentafluoroethyl-benzoic acid

- 5 A mixture of 4-pentafluoroethyl-benzonitrile (2.98 g, 13.5 mmol) and potassium hydroxide (3.03 g, 54.0 mmol) in water (40 mL) and ethanol (20 mL) was heated at reflux for 16 h. After cooling, the solution was partitioned between 1 M aq. hydrochloric acid solution and ethyl acetate. The organic layer was washed with brine, dried (MgSO_4), and evaporated. Chromatography (SiO_2 , heptane-ethyl acetate gradient) produced the title
10 compound (2.76 g, 85%). White solid, MS (ISP) 238.9 (M-H^-).

Example S6-A: Preparation of 4-trimethylsilyl-benzaldehyde

- 1-Bromo-4-(trimethylsilyl)benzene (1.15 g, 5 mmol) was dissolved in THF (30 mL) and cooled to -78°C . Under argon a 1.6 M solution of n-butyl lithium in hexane (3.13 mL, 5 mmol) was added dropwise keeping the temperature below -70°C . The clear colorless
15 solution was stirred at -78°C for 15 min and DMF (1.156 mL, 15 mmol) was added quickly. The reaction temperature increased to -68°C . The reaction was stirred for additional 15 min at -78°C , quenched with 1N aqueous hydrogen chloride solution and extracted twice with diethyl ether. The combined organic layers were washed twice with water and once
20 with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and the solvent was evaporated to leave the product as a colorless oil (920 mg, 100 %). The product was pure enough to be used directly in the next step. MS (ISP) 179.2 ($\text{M}+\text{H}^+$). ^1H NMR (CDCl_3 , 300MHz): δ 10.02 (s, 1H) 7.84 (d, 2H), 7.69 (d, 2H), 0.31 (s, 9H).

Example S7-A: Preparation of 4-(1,1-dimethylpropyl)-benzaldehyde

The title compound was synthesized in analogy to example S1-A using 1-bromo-4-(1,1-dimethylpropyl)-benzene (synthesized in analogy to a procedure described in *J.Chem. Res. Miniprint.*, 1997, 12, 2701-2733) (250mg, 1.10mmol), *n*BuLi (825 μ l, 1.6M solution in
5 hexane, 1.32mmol) and DMF (427 μ l, 5.50mmol). The isolated residue was purified by flash column chromatography (1:9 ether:pentane) to give 4-(1,1-dimethylpropyl)-benzaldehyde (175mg, 90%) as a colourless oil. ¹H NMR (CDCl₃, 300MHz): 9.99 (s, 1H), 7.82 (d, J=8.5Hz, 2H), 7.50 (d, J=8.5Hz, 2H), 1.69 (q, J=7.5Hz, 2H), 1.32 (s, 6H), 0.68 (t, J=7.5Hz, 3H).

10 Primary amines (Compounds of formula V):

Example S1-B: Preparation of 2-(3-fluoro-5-trifluoromethyl-phenyl)-ethylamine hydrochloride

5.45 g of (3-fluoro-5-trifluoromethyl-phenyl)-acetonitrile (26.3 mmol) were dissolved in 45 ml THF and cooled down to 0°C under nitrogen. 138 ml borane-tetrahydrofuran complex 1M (138 mmol) were then added dropwise over 20 min by keeping the temperature
15 between 0-2°C. After addition the reaction mixture was stirred at RT for additional 45 min, and refluxed for 17 h. The reaction mixture is then cooled down to 0°C and treated between 2 and 5°C with 33 ml methanol over a period of 45 min. After 1 hour refluxing the reaction mixture is concentrated, the residue dissolved in DCM and the amine extracted
20 twice with 1N aqueous HCl. The combined aqueous phases are then treated with concentrated NaOH to adjust the pH to 12, and then extracted twice with DCM. The combined organic phases were then washed with water, dried over magnesium sulfate, filtered and concentrated in vacuo leading to 4.44 g colorless oil. This was dissolved in 100 ml diethylether, treated with 9 ml 2.6N HCl in diethylether, stirred at RT for additional 30 min,
25 filtered and dried under high vacuo, leading to 4.6 g white solid (72 %). MS (ISP) 207.1 (M+H)⁺.

Example S2-B: Preparation of 2-(4-chloro-3-trifluoromethyl-phenyl)-ethylamine hydrochloride

a) Preparation of (4-chloro-3-trifluoromethyl-phenyl)-acetonitrile:
30 3.94 g of 4-bromomethyl-1-chloro-2-trifluoromethyl-benzene (14.4 mmol) and 1.06 g sodium cyanide (21.6 mmol) were suspended in 12 ml DMSO under argon and stirring

and heated to 50°C for 1 h. The reaction mixture was then poured on water/ice and extracted four times with DCM. The combined organic phases were washed with water, dried with magnesium sulfate, filtered and concentrated in *vacuo*, leading to 3.188 g of (4-chloro-3-trifluoromethyl-phenyl)-acetonitrile as a dark red oil, which was directly used in the next step.

b) Preparation of 2-(4-chloro-3-trifluoromethyl-phenyl)-ethylamine hydrochloride:
The title compound was synthesized in analogy to 2-(3-fluoro-5-trifluoromethyl-phenyl)-ethylamine hydrochloride (described in example S1-B) from 3.188 g of crude (4-chloro-3-trifluoromethyl-phenyl)-acetonitrile (14.5 mmol) and 76 ml of a 1M borane-THF complex solution in THF (76 mmol). The product was obtained as a white solid (1.52 g, 40%). MS (ISP) 224.1 (M+H)⁺.

Example S3-B: Preparation of 2-(4-chloro-3-fluoro-phenyl)-ethylamine (S3-B1)

a) Preparation of 1-chloro-2-fluoro-4-(2-nitro-vinyl)-benzene:
4-Chloro-3-fluorobenzaldehyde (13g, 82mmol) and ammonium acetate (14.6g, 189mmol) were dissolved in acetic acid (150ml) and nitromethane (12.6ml, 234mmol) was added. The solution was heated to reflux for 1.5h. After cooling to RT water (120ml) was added. A solid precipitated. The reaction was extracted three times with methylene chloride. The combined organic layers were washed with water and sat. aq. NaCl solution, dried over magnesium sulfate, filtered and the solvent was removed in *vacuo*. The residue was purified by flash column chromatography (Ethyl acetate/cyclohexane:1/4). The crude product was suspended in heptane, filtered and dried to yield 1-chloro-2-fluoro-4-(2-nitro-vinyl)-benzene (10.9g, 66%) as a light yellow solid. ¹H NMR (CDCl₃, 300MHz): δ 7.29 (d, J=7.8 Hz, 1H), 7.33 (d, J=9.3 Hz, 1H), 7.50 (t, J=7.5 Hz, 1H), 7.54 (d, J=13.6Hz, 1H), 7.92 (d, J=13.6 Hz, 1H).

b) Preparation of 2-(4-chloro-3-fluoro-phenyl)-ethylamine:
Lithium borohydride (2.16g, 99 mmol) was suspended in THF (50ml). Trimethylchlorosilane (21.6g, 198mmol) was added dropwise. A solution of 1-chloro-2-fluoro-4-(2-nitro-vinyl)-benzene (5.0g, 24.8mmol) in THF (20ml) was added dropwise. Strong gas evolution and foam formation was observed. The white suspension was stirred at RT for 3 days. Carefully MeOH (80ml) was added. The solvents were removed in *vacuo* and the residue was purified by flash column chromatography (CH₂Cl₂ / MeOH+5%aq. NH₄OH 4:1) to yield 2-(4-chloro-3-fluoro-phenyl)-ethylamine (3.1g, 73%) as a white solid. MS (ISP)

174.1 (M+H)⁺. ¹H NMR (DMSO-d₆, 300 MHz): δ 2.92 (t, J=4.8 Hz, 2H), 3.02 (t, J=6.3 Hz, 2H), 7.15 (dd, J=6.0 and 1.2 Hz, 1H), 7.38 (dd, J=1.2 and 7.8 Hz), 7.53 (t, J=6.3 Hz, 1H), 7.93 (br, 2H).

Example	Name	*	MS (ISP)
S3-B2	2-(3-Chloro-5-fluoro-phenyl)-ethylamine hydrochloride	S1-B	174.0 (M+H) ⁺
S3-B3	2-(3-Chloro-4-fluoro-phenyl)-ethylamine hydrochloride	S1-B	174.1 (M+H) ⁺
S3-B4	2-(3-Trifluoromethoxy-phenyl)-ethylamine hydrochloride	S1-B	206.2 (M+H) ⁺
S3-B5	2-(3,5-Dichloro-phenyl)-ethylamine hydrochloride	S3-B	190.2 (M+H) ⁺
S3-B6	2-(3-Chloro-5-trifluoromethyl-phenyl)-ethylamine hydrochloride	S1-B	222.2 (M+H) ⁺
S3-B7	2-(4-Fluoro-3-trifluoromethyl-phenyl)-ethylamine hydrochloride	S1-B	208.2 (M+H) ⁺
S3-B8	2-(3-Benzoyloxy-phenyl)-ethylamine hydrochloride	S3-B	228.4 (M+H) ⁺
S3-B9	3-(3-Trifluoromethyl-phenyl)-propylamine hydrochloride	S1-B	204.1 (M+H) ⁺
S3-B10	3-(3-Chloro-phenyl)-propylamine hydrochloride	S1-B	170.0 (M+H) ⁺
S3-B11	3-(4-Chloro-phenyl)-propylamine hydrochloride	S1-B	170.0 (M+H) ⁺
S3-B12	2-(3-Bromo-4-fluoro-phenyl)-ethylamine	S3-B	201.1 (M+H) ⁺

*: Prepared in analogy to example

5 Example S4-B: Preparation of 2-(3-bromo-4-chlorophenyl)-ethylamine:

a) Preparation of (3-bromo-4-chlorophenyl)-acetonitrile:

The title compound was synthesized in analogy to example S2-B using 2-bromo-4-bromomethyl-1-chlorobenzene (prepared in analogy to a procedure described in J.Med.Chem.; 2003; 46(20), 4232 – 4235) (570 mg, 2.00 mmol) and sodium cyanide (147 mg, 3.00 mmol) to give the desired product as a dark red oil which was reacted on without further purification.

b) Preparation of 2-(3-bromo-4-chlorophenyl)-ethylamine:

The title compound was synthesized in analogy to example S1-B using crude (3-bromo-4-chlorophenyl)-acetonitrile (475 mg, 2.06 mmol) and 1M borane-THF complex (4.12 ml,

4.12mmol). The product was obtained as a colorless oil (300 mg, 62%). MS (ISP) 236.0 (M+H)⁺.

Example S5-B: Preparation of 2-(4-chloro-3-ethyl-phenyl)-ethylamine hydrochloride

a) Preparation of 4-chloro-3-ethyl-benzaldehyde:

To a solution of 4.319 g of 4-bromo-1-chloro-2-ethyl-benzene (20 mmol) in 50 ml diethylether, cooled to 0°C, were added dropwise 12.3 ml of 1.6M n-BuLi in hexane. After 30 min. stirring at 0°C and 2 h at RT, a solution of 2.43 ml DMF (31 mmol) in 10 ml diethylether was added dropwise (temperature raised from 20 to 28°C). After 1 h additional stirring at RT, the reaction mixture was acidified with 2N HCl, diluted with 150 ml water and extracted with diethylether. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered off and concentrated in vacuo. The residue was purified by flash column chromatography (heptane / AcOEt: 95/5) to yield 2.1 g of a colorless oil. MS (ISP) 168.1 (M+H)⁺.

b) Preparation of 2-(4-chloro-3-ethyl-phenyl)-ethylamine hydrochloride:

The title compound was prepared from 4-chloro-3-ethyl-benzaldehyde in analogy to example S3-B1 steps a) and b). MS (ISP) 184.1 (M+H)⁺.

Example S6-B: Preparation of 2-(4-benzyloxy-3-tert-butyl-phenyl)-ethylamine hydrochloride

a) 1-Benzyloxy-2-tert-butyl-4-methyl-benzene:

8 g of 2-tert-Butyl-4-methyl-phenol (49 mmol) and 16.36 g of potassium carbonate (58 mmol) were stirred in 120 ml DMF until a suspension was formed. 6.74 ml of benzylchloride were then added dropwise and the reaction mixture was stirred for 24 h at RT. After two hours heating at 60°C, the reaction mixture was cooled to RT, filtered off, diluted with ethyl acetate, and washed with water followed by brine. The organic phase was dried over magnesium sulphate, filtered off and concentrated under vacuo. The residue was purified by flash column chromatography (heptane/AcOEt 98/2) to give 8.647 g of a colourless liquid. MS (ISP) 255.3 (M+H)⁺.

b) Preparation of 4-benzyloxy-3-tert-butyl-benzaldehyde:

A solution of 6.985 g 1-benzyloxy-2-tert-butyl-4-methyl-benzene (27 mmol) and 115 g ammoniumcer(IV)-nitrate in 1000 ml acetic acid (50%v/v) was stirred at 90°C for one hour. After cooling down to RT, the reaction mixture was extracted with AcOEt/heptane 1:9, dried over magnesium sulfate, filtered off and concentrated under vacuo. The residue was purified by flash column chromatography (heptane/AcOEt 95/5 to 90/10) to give 3.48 g of an orange solid. MS (ISP) 269.3 (M+H)⁺.

c) Preparation of 2-(4-benzyloxy-3-tert-butyl-phenyl)-ethylamine hydrochloride:

The title compound was prepared from 4-benzyloxy-3-*tert*-butyl-benzaldehyde in analogy to example S3-B1 steps a) and b). MS (ISP) 284.2 (M+H)⁺.

Secondary amines (Compounds of formula III):

Example S1-C: Preparation of (4-*tert*-butyl-benzyl)-[2-(3,4-dichloro-phenyl)-ethyl]-amine

0.38 ml of 4-*tert*-butylbenzaldehyde (2.25 mmol) and 0.227 ml 2-(3,4-dichloro-phenyl)-ethylamine (1.5 mmol) were dissolved in 4.5 ml methanol at RT, and after stirring for 30 min at RT, were refluxed for 2 h. After cooling down to RT, 85 mg (2.25 mmol) sodium borohydride were added and after stirring for 5 min at RT, the reaction mixture was then
10 refluxed for 2 h. After cooling down to RT, the reaction mixture was treated with 4 drops 1 N HCl and concentrated in *vacuo*. The residue was diluted with water/ EtOAc. After separation of the organic phase, the aqueous phase was extracted with EtOAc and the combined organic phases were washed with brine, dried with magnesium sulfate, filtered off and concentrated in *vacuo*. The residue was purified by column chromatography (40 g
15 silica gel; EtOAc /heptane 1:2) to give 515 mg colorless viscous oil (97 %). MS (ISP) 336.2 (M+H)⁺.

Example S2-C: Preparation of (4-*tert*-butyl-benzyl)-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-amine

0.62 ml of 4-*tert*-butylbenzaldehyde (3.69 mmol), 600 mg of 2-(4-fluoro-3-trifluoro-methyl-phenyl)-ethylamine hydrochloride (2.46 mmol) and 340 mg of potassium carbonate
20 (2.46 mmol) were suspended in 7 ml methanol at RT, and after stirring for 30 min at RT, were refluxed for 2 h. After cooling down to RT, 140 mg (3.69 mmol) of sodium borohydride were added and after stirring for 5 min at RT, the reaction mixture was then refluxed for 3 h. After cooling down to RT, the reaction mixture was treated with 0.5 ml 1 N
25 HCl and concentrated in *vacuo*. The residue was diluted with water/ EtOAc. After separation of the organic phase, the aqueous phase was extracted with EtOAc and the combined organic phases were washed with brine, dried with magnesium sulfate, filtered off and concentrated in *vacuo*. The residue was purified by column chromatography (40 g silica gel; EtOAc /heptane 1:4 then 1:2) to give 784 mg light yellow oil (90 %). MS (ISP) 354.3
30 (M+H)⁺.

Example S3-C: Preparation of (4-cyclopropylbenzyl)-[2-(3,4-dichlorophenyl)-ethyl]-amine

A mixture of 4-cyclopropyl benzaldehyde (219mg, 1.50 mmol), 2-(3,4-dichlorophenyl)-ethylamine (284mg, 1.50 mmol) and molecular sieves (500 mg, 4Å) in diethyl ether (5ml) was stirred at RT overnight. The mixture was filtered through celite® and concentrated in *vacuo* to give the corresponding imine which was dissolved in methanol. Sodium borohydride (85 mg, 2.25 mmol) was added and the reaction mixture was stirred at RT for 4h. The reaction mixture was then quenched with 0.1N NaOH (aq) and the mixture was diluted with EtOAc and washed with brine. The organic phase was dried (MgSO₄), filtered and concentrated in *vacuo* to give the desired (4-cyclopropylbenzyl)-[2-(3,4-dichlorophenyl)-ethyl]-amine (317mg, 75%) without further purification as a colourless oil. MS (ISP) 320.2 (M+H)⁺.

Example S4-C: Preparation of (4-tert-butyl-benzyl)-[2-(2-chloro-pyridin-4-yl)-ethyl]-amine

15 a) Preparation of 2-chloro-4-trimethylsilanylethynyl-pyridine:

A mixture of 2.5 g of 4-bromo-2-chloropyridine (12.6 mmol), 2.2 ml of (trimethylsilyl)-acetylene (15.1 mmol), 153 mg of copper(I)iodide (0.79 mmol) and 287 mg of bis(triphenylphosphine)palladium(II)chloride (0.41 mmol) in triethylamine (15 ml) was stirred at RT for 1 h. The triethylamine was then removed in *vacuo*, water was added and the mixture was extracted with diethylether. The combined organic extracts were then washed with water and brine, dried (Na₂SO₄), filtered and concentrated in *vacuo* to give a residue which was purified by column chromatography (heptane/EtOAc 100:0 to 98:2) to give 2-chloro-4-trimethylsilanylethynyl-pyridine (2.394 g, 91%) as a light yellow liquid. MS (ISP) 210.1 (M+H)⁺.

25 b) Preparation of 2-chloro-4-ethynyl-pyridine:

To a solution of 2.389 g of 2-chloro-4-trimethylsilanylethynyl-pyridine (11.39 mmol) in THF (90 ml) were added 11.39 ml of a 1M TBAF solution in THF at -78°C and the reaction mixture was stirred for 45 min at 0°C. Then saturated NH₄Cl solution was added and the THF was removed under reduced pressure. The aqueous mixture was extracted with diethylether and the combined organic extracts were washed with water and brine, dried (Na₂SO₄), filtered and concentrated in *vacuo*. The remaining residue was purified by column chromatography (pentane/diethylether 100:0 to 4:1) to give 2-chloro-4-ethynyl-

pyridine (1.427 g, 91%) as an off-white solid. ^1H -NMR (CDCl_3 , 300 MHz: δ 3.36 (s, 1H), 7.27 (dd, $J=5$ and 1 Hz, 2H), 7.40 (br s, 1H), 8.37 (d, $J=8$ Hz, 2H).

c) Preparation of (4-*tert*-butyl-benzyl)-[2-(2-chloro-pyridin-4-yl)-ethyl]-amine:

- A mixture of 1.386 g of 2-chloro-4-ethynyl-pyridine (10.07 mmol), 2.65 ml of 4-*tert*-butylbenzylamine (15.11 mmol), 0.58 ml of acetic acid (10.07 mmol) and 666 mg of sodium cyanoborohydride (95% purity, 10.07 mmol) in ethanol (12 ml) were heated to 105°C in a sealed tube for 2 d. The reaction mixture was allowed to cool to RT, diluted with 3N NaOH solution and extracted with DCM. The combined organic extracts were washed with saturated NaHCO_3 solution and brine, dried (Na_2SO_4), filtered and concentrated in *vacuo*. After column chromatography (heptane/EtOAc 100:0 to 0:100) 1.688 g (55%) of the title compound were isolated as a brown liquid. MS (ISP) 303.2 ($\text{M}+\text{H}$) $^+$.

Example S5-C: Preparation of (4-*tert*-butylbenzyl)-[2-(4-chloro-3-trifluoromethylpyrazol-1-yl)-ethyl]-amine and (4-*tert*-butylbenzyl)-[2-(4-chloro-5-trifluoromethylpyrazol-1-yl)-ethyl]-amine

- 15 a) Preparation of 4-chloro-3-trifluoromethyl-1*H*-pyrazole:

To a solution of 3-trifluoromethyl-1*H*-pyrazole (500 mg, 3.67 mmol) in glacial acetic acid (5 ml) was added a 10% solution of sodium hypochlorite in water (2188 μl , 3.67 mmol). The reaction mixture was stirred at RT overnight and then neutralized with sat. sodium carbonate, and extracted with DCM. The organic layers were combined washed with brine, dried (MgSO_4), filtered and concentrated in *vacuo* to give the desired product (480 mg, 77%) as a white solid which did not require further purification. MS (ISP) 169.0 ($\text{M}-\text{H}$) $^-$.

b) Preparation of 2-(4-*tert*-butylbenzylamino)-ethanol:

- The title compound was synthesized in analogy to example S3-C using 4-*tert*-butylbenzaldehyde (1000 mg, 6.17 mmol), ethanolamine (371 μl , 6.17 mmol) and sodium borohydride (350 mg, 9.25 mmol). The desired product (1190 mg, 93%) was isolated without further purification as a colourless oil. MS (ISP) 208.3 ($\text{M}+\text{H}$) $^+$.

c) Preparation of 3-(4-*tert*-butylbenzyl)-[1,2,3]oxathiazolidine 2,2-dioxide:

- To a solution of 2-(4-*tert*-butylbenzylamino)-ethanol (1190 mg, 5.74 mmol) and triethylamine (3200 μl , 22.96 mmol) in DCM (15 ml) at -15°C was added a solution of thionyl chloride (544 μl , 7.46 mmol) in DCM (4 ml) over 10 min. The reaction mixture was stirred at -10°C for 30min, filtered and the filtrate was concentrated in *vacuo*. The residue was purified by flash column chromatography to give the desired compound (790 mg, 54%) as

a white solid. To a mixture of 3-(4-*tert*-butylbenzyl)-[1,2,3]oxathiazolidine 2-oxide (790 mg, 3.12 mmol) in DCM (20 ml), acetonitrile (8 ml) and water (8 ml), at 0°C was added NaIO₄ (867 mg, 4.05 mmol) followed by RuO₂ (2mg). The reaction mixture was stirred at 0°C for 2h. Water was added and the phases were separated and the aqueous phase was
5 extract with ethyl acetate. The organic layers were combined washed with brine, dried (MgSO₄), and concentrated in *vacuo*. The residue was then purified by flash column chromatography to give the desired product (640 mg, 76%) as an off white solid. MS (ISP) 287.0 (M+NH₄)⁺.

d) Preparation of (4-*tert*-butylbenzyl)-[2-(4-chloro-3-trifluoromethylpyrazol-1-yl)-ethyl]-amine and (4-*tert*-butylbenzyl)-[2-(4-chloro-5-trifluoromethylpyrazol-1-yl)-ethyl]-amine:
10 To a suspension of NaH (67 mg, 1.67 mmol) in THF (10 ml) at 0°C was added a solution of 4-chloro-3-trifluoromethyl-1*H*-pyrazole (190 mg, 1.11 mmol) in THF (5 ml) dropwise. The reaction mixture was stirred at 0°C for 30 min and then 3-(4-*tert*-butylbenzyl)-[1,2,3]oxathiazolidine 2,2-dioxide (300 mg, 1.11 mmol) was added portion wise. The
15 reaction mixture was warmed to RT and stirred for a further 3h after which the reaction mixture was quenched with 5ml 20% (v/v) H₂SO₄. The reaction mixture was warmed to 60°C overnight and then cooled to RT and poured into water. The aqueous phase was made basic with 1N NaOH and then extracted with ethyl acetate. The organic layers were combined, washed with brine, dried over MgSO₄, filtered and concentrated in *vacuo* to give
20 a 4:1 mixture of regioisomers (4-*tert*-butylbenzyl)-[2-(4-chloro-3-trifluoromethylpyrazol-1-yl)-ethyl]-amine (210 mg, 52%) MS (ISP) 360.1 (M+H)⁺ and (4-*tert*-butylbenzyl)-[2-(4-chloro-5-trifluoromethylpyrazol-1-yl)-ethyl]-amine (50 mg, 13%) MS (ISP) 360.1 (M+H)⁺ respectively which were separated by flash column chromatography.

Example S6-C: Preparation of (4-*tert*-butylbenzyl)-[2-(3-cyclopropylphenyl)-ethyl]-amine
25

To a solution of *m*-bromophenylcyclopropane (synthesized as described in *J.Org.Chem.* 1976, 41, 2262-2266) (100 mg, 0.51 mmol) in dry THF (3 ml) at -78°C was added *n*BuLi (317 µl, 1.6M solution in hexane, 0.51 mmol) dropwise. The reaction mixture was stirred at -78°C for 10 min and then a solution of 3-(4-*tert*-butylbenzyl)-[1,2,3]oxathiazolidine
30 2,2-dioxide (109mg, 0.41mmol) in THF (1ml) was added dropwise. The reaction mixture was warmed to 0°C over 3 hours and then quenched with 5ml 20% (v/v) H₂SO₄. The reaction mixture was warmed to 60°C overnight and then cooled to RT and poured into water. The aqueous phase was made basic with 1N NaOH and then extracted with ethyl

acetate. The organic layers were combined, washed with brine, dried over MgSO_4 , filtered and concentrated in *vacuo* to give a crude residue which was purified by flash column chromatography to give (4-*tert*-butylbenzyl)-[2-(3-cyclopropylphenyl)-ethyl]-amine (72mg, 58%) as a colourless oil. MS (ISP) 308.4 ($\text{M}+\text{H}$)⁺.

5 Example S7-C: Preparation of (4-*tert*-butylbenzyl)-[2-(3-chloro-5-cyclopropylphenyl)-ethyl]-amine

a) Preparation of 1-bromo-3-chloro-5-cyclopropylbenzene:

To a solution of 1,3-dibromo-5-chlorobenzene (500 mg, 1.85 mmol) in THF (1 ml) was added cyclopropylmagnesium bromide (3698 μl , 0.5M solution in THF, 1.85 mmol) in a
10 sealed tube and the reaction mixture was degassed with argon for 5 min before tetrakis-(triphenylphosphine)palladium (0) (107 mg, 0.09 mmol) was added. The resulting solution was heated to 70°C overnight, cooled to RT and then quenched with sat. NH_4Cl solution and extracted with pentane. The organic phases were combined, washed with water and brine, dried over MgSO_4 and filtered through a short pad of silica gel to give the
15 desired product (272 mg, 64%) which did not require further purification. ^1H NMR (CDCl_3 , 300MHz): 7.28 (appt, $J=2.0\text{Hz}$, 1H), 7.08 (appt, $J=1.5\text{Hz}$, 1H), 6.97 (appt, $J=1.5\text{Hz}$, 1H), 1.83 (m, 1H), 1.04-0.97 (m, 2H), 0.72-0.67 (m, 2H).

b) Preparation of (4-*tert*-butylbenzyl)-[2-(3-chloro-5-cyclopropylphenyl)-ethyl]-amine:

The title compound was synthesized in analogy to example S6-C using 1-bromo-3-chloro-
20 5-cyclopropylbenzene (96 mg, 0.71 mmol) and 3-(4-*tert*-butylbenzyl)-[1,2,3]oxathiazolidine 2,2-dioxide (36 mg, 0.89 mmol). The residue was purified by flash column chromatography to give the desired product (155 mg, 39%) as a colourless oil. MS (ISP) 342.2 ($\text{M}+\text{H}$)⁺.

25 Example S8-C: Preparation of (4-*tert*-butylbenzyl)-[2-(3-cyclopropyl-4-fluorophenyl)-ethyl]-amine

a) Preparation of 3-cyclopropyl-4-fluorophenylamine:

To a solution of 3-bromo-4-fluorophenylamine (synthesized as described in *J.Org.Chem.* 1981, 46, 2280-2286) (415 mg, 2.18 mmol), cyclopropyl boronic acid (244 mg, 2.84 mmol), potassium phosphate (1.62 g, 7.64 mmol), and tricyclohexyl phosphine (61 mg, 0.22
30 mmol) in toluene (10 ml) and water (0.5 ml) was added palladium acetate (25 mg, 0.11 mmol) and the reaction mixture was heated to 100°C overnight. The mixture was then cooled to RT and diluted with water and extracted with ether. The organic phases were

combined, washed with brine, dried (MgSO_4), filtered and concentrated *in vacuo* to give a residue which was purified by flash column chromatography to give 3-cyclopropyl-4-fluorophenylamine (210 mg, 64%). MS (ISP) 152.2 ($\text{M}+\text{H}$)⁺.

b) Preparation of 2-cyclopropyl-1-fluoro-4-iodobenzene:

- 5 To a solution of 3-cyclopropyl-4-fluorophenylamine (210 mg, 1.39 mmol) in DME (1.5 ml) was added caesium iodide (360 mg, 1.39 mmol), cuprous iodide (82 mg, 0.43 mmol), iodine (176 mg, 0.70 mmol) and isoamyl nitrite (1.11 ml, 8.34 mmol). The reaction mixture was heated to 60°C for 2 h. The reaction mixture was cooled to RT and partitioned between pentane and sat. NH_4Cl solution. The organic layer was separated, washed with
- 10 5% sodium thiosulfite and brine, dried (MgSO_4), filtered and concentrated *in vacuo* to give a residue which was purified by flash column chromatography (100% pentane) to yield the desired 2-cyclopropyl-1-fluoro-4-iodobenzene (262 mg, 72%) as a colourless oil. ^1H NMR (CDCl_3 , 300MHz): 7.40 (m, 1H), 7.17 (m, 1H), 6.76 (m, 1H), 2.02 (m, 1H), 1.03-0.96 (m, 2H), 0.74-0.68 (m, 2H).

- 15 c) Preparation of (4-*tert*-butylbenzyl)-[2-(3-cyclopropyl-4-fluorophenyl)-ethyl]-amine: The title compound was synthesized in analogy to example S6-C using 2-cyclopropyl-1-fluoro-4-iodobenzene (100 mg, 0.38 mmol) and 3-(4-*tert*-butylbenzyl)-[1,2,3]oxathiazolidine 2,2-dioxide (103 mg, 0.38 mmol). The residue was purified by flash column chromatography to give the desired product (35 mg, 28%) as a colourless oil. MS (ISP) 326.3
- 20 ($\text{M}+\text{H}$)⁺.

Example S9-C: Preparation of [2-(4-fluoro-phenyl)-ethyl]-(4-pentafluoroethyl-benzyl)-amine (S9-C1)

a) Preparation of N-[2-(4-fluoro-phenyl)-ethyl]-4-pentafluoroethyl-benzamide

- A solution of 4-pentafluoroethyl-benzoic acid (500 mg, 2.08 mmol), 2-(4-fluorophenyl)-ethylamine (319 mg, 2.29 mmol), 4-methylmorpholine (632 mg, 6.24 mmol), and HBTU (1.19 g, 3.12 mmol) in DMF (38 mL) was stirred at RT for 16 h, then the reaction mixture was partitioned between water and ethyl acetate. The organic layer was washed with brine, dried (MgSO_4), and evaporated. Chromatography (SiO_2 , heptane-ethyl acetate gradient) afforded the title compound (746 mg, 99%). White solid, MS (ISP) 362.2 ($\text{M}+\text{H}$)⁺.
- 25

- 30 b) Preparation of [2-(4-fluoro-phenyl)-ethyl]-(4-pentafluoroethyl-benzyl)-amine
Borane-tetrahydrofuran complex solution (1 M in THF, 6.5 mL, 6.5 mmol) was added at 0°C to a solution of N-[2-(4-fluoro-phenyl)-ethyl]-4-pentafluoroethyl-benzamide (740

mg, 2.04 mmol) in THF (8 mL), and the homogeneous solution was heated at reflux over 3 h. After cooling, excess reagent was destroyed by careful addition of methanol at 0°C. Volatile material was removed by distillation, then the residue was dissolved in 5% ethanolic sulfuric acid solution (5 mL). The solution was refluxed for 90 min, then partitioned between 2 M aq. sodium hydroxide solution and ethyl acetate. The organic layer was washed with brine, dried (MgSO₄), and evaporated. Chromatography (SiO₂, DCM/methanol/NH₄OH 95:5:0.1) afforded the title compound (652 mg, 92%). Colourless oil, MS (ISP) 348.2 (M+H)⁺.

Example	Name	*	MS (ISP)
S9-C2	(4- <i>tert</i> -Butyl-benzyl)-[2-(3-trifluoromethyl-phenyl)-ethyl]-amine	S1-C	336.3 (M+H) ⁺
S9-C3	(4- <i>tert</i> -Butyl-benzyl)-phenethyl-amine	S1-C	268.3 (M+H) ⁺
S9-C4	(4- <i>tert</i> -Butyl-benzyl)-[2-(3-trifluoromethoxy-phenyl)-ethyl]-amine	S2-C	352.3 (M+H) ⁺
S9-C5	(4- <i>tert</i> -Butyl-benzyl)-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-amine	S2-C	370.2 (M+H) ⁺
S9-C6	(4-Cyclobutylbenzyl)-[2-(3-trifluoromethoxy-phenyl)-ethyl]-amine	S2-C	350.3 (M+H) ⁺
S9-C7	Butyl-(4- <i>tert</i> -butyl-benzyl)-amine	S1-C	220.4 (M+H) ⁺
S9-C8	(4- <i>tert</i> -Butyl-benzyl)-[2-(3-chloro-4-fluoro-phenyl)-ethyl]-amine	S2-C	320.3 (M+H) ⁺
S9-C9	[2-(4-Chloro-phenyl)-ethyl]-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-benzyl]-amine	S1-C	414.3 (M+H) ⁺
S9-C10	(4-Cyclobutyl-benzyl)-[2-(3-trifluoromethyl-phenyl)-ethyl]-amine	S1-C	334.4 (M+H) ⁺
S9-C11	(4-Cyclobutyl-benzyl)-[2-(4-fluoro-phenyl)-ethyl]-amine	S1-C	284.4 (M+H) ⁺
S9-C12	[2-(4-Chloro-phenyl)-ethyl]-(4-cyclobutyl-benzyl)-amine	S1-C	300.4 (M+H) ⁺
S9-C13	(4- <i>tert</i> -Butyl-benzyl)-[2-(4-fluoro-phenyl)-ethyl]-amine	S1-C	286.2 (M+H) ⁺
S9-C14	(4- <i>tert</i> -Butyl-benzyl)-[2-(4-chloro-phenyl)-ethyl]-amine	S1-C	302.3 (M+H) ⁺
S9-C15	(4- <i>tert</i> -Butyl-benzyl)-[2-(3-chloro-phenyl)-ethyl]-	S1-C	302.3 (M+H) ⁺

	amine		
S9-C16	[4-(1-Fluoro-cyclobutyl)-benzyl]-[2-(3-trifluoromethyl-phenyl)-ethyl]-amine	S1-C	352.4 (M+H) ⁺
S9-C17	[2-(3,4-Dichloro-phenyl)-ethyl]-[4-(1-fluoro-cyclobutyl)-benzyl]-amine	S1-C	352.3 (M+H) ⁺
S9-C18	(4-tert-Butyl-benzyl)-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-amine	S4-C	337.3 (M+H) ⁺
S9-C19	[2-(4-Chloro-phenyl)-ethyl]-(4-trifluoromethoxy-benzyl)-amine	S1-C	330.2 (M+H) ⁺
S9-C20	[2-(4-Chloro-phenyl)-ethyl]-(4-trifluoromethyl-benzyl)-amine	S1-C	313.9 (M+H) ⁺
S9-C21	[2-(3-Trifluoromethyl-phenyl)-ethyl]-(4-trimethylsilanyl-benzyl)-amine	S1-C	352.4 (M+H) ⁺

S9-C22	[2-(4-Chloro-phenyl)-ethyl]-(4-trimethylsilanyl-benzyl)-amine	S1-C	318.1 (M+H) ⁺
S9-C23	[2-(4-Fluoro-phenyl)-ethyl]-(4-trimethylsilanyl-benzyl)-amine	S1-C	302.2 (M+H) ⁺
S9-C24	[2-(3,4-Dichloro-phenyl)-ethyl]-(4-trimethylsilanyl-benzyl)-amine	S1-C	352.2 (M+H) ⁺
S9-C25	(4-tert-Butyl-benzyl)-[2-(4-chloro-3-fluoro-phenyl)-ethyl]-amine	S1-C	320.3 (M+H) ⁺
S9-C26	[2-(3-Trifluoromethoxy-phenyl)-ethyl]-(4-trimethylsilanyl-benzyl)-amine	S1-C	368.2 (M+H) ⁺
S9-C27	[2-(4-Chloro-phenyl)-ethyl]-[4-(1-fluoro-cyclobutyl)-benzyl]-amine	S3-C	318.1 (M+H) ⁺
S9-C28	[4-(1-Fluoro-cyclobutyl)-benzyl]-[2-(4-fluoro-phenyl)-ethyl]-amine	S3-C	302.3 (M+H) ⁺
S9-C29	[2-(3-Chloro-phenyl)-ethyl]-[4-(1-fluoro-cyclobutyl)-benzyl]-amine	S3-C	318.1 (M+H) ⁺
S9-C30	[2-(4-Chloro-phenyl)-ethyl]-[4-(1,1-dimethyl-propyl)-benzyl]-amine	S1-C	316.1 (M+H) ⁺
S9-C31	[4-(1,1-Dimethyl-propyl)-benzyl]-[2-(3-trifluoromethyl-phenyl)-ethyl]-amine	S3-C	350.3 (M+H) ⁺

S9-C32	(4-tert-Butyl-benzyl)-(3-phenyl-propyl)-amine	S1-C	282.3 (M+H) ⁺
S9-C33	(4-tert-Butyl-benzyl)-[2-(3-cyclopropyl-5-fluoro-phenyl)-ethyl]-amine	S7-C	326.2 (M+H) ⁺
S9-C34	(4-tert-Butyl-benzyl)-[2-(3-chloro-5-fluoro-phenyl)-ethyl]-amine	S2-C	320.1 (M+H) ⁺
S9-C35	(4-tert-Butyl-benzyl)-[2-(3-chloro-5-trifluoro-methyl-phenyl)-ethyl]-amine	S2-C	370.0 (M+H) ⁺
S9-C36	(4-tert-Butyl-benzyl)-[2-(3-fluoro-5-trifluoro-methyl-phenyl)-ethyl]-amine	S2-C	354.3 (M+H) ⁺
S9-C37	[2-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-(4-tert-butyl-benzyl)-amine	S1-C	404.5 (M+H) ⁺
S9-C38	(4-tert-Butyl-benzyl)-[2-(3,5-dichloro-phenyl)-ethyl]-amine	S1-C	336.0 (M+H) ⁺
S9-C39	(4-tert-Butyl-benzyl)-(2-p-tolyl-ethyl)-amine	S1-C	282.2 (M+H) ⁺
S9-C40	(4-tert-Butyl-benzyl)-[2-(4-trifluoromethyl-phenyl)-ethyl]-amine	S1-C	336.2 (M+H) ⁺
S9-C41	[2-(3-Bromo-phenyl)-ethyl]-(4-tert-butyl-benzyl)-amine	S1-C	346.1 (M+H) ⁺
S9-C42	[2-(3-Bromo-4-chlorophenyl)-ethyl]-(4-tert-butylbenzyl)-amine	S3-C	382.3 (M+H) ⁺
S9-C43	[2-(3-Benzoyloxy-phenyl)-ethyl]-(4-tert-butyl-benzyl)-amine	S2-C	374.3 (M+H) ⁺
S9-C44	(4-tert-Butyl-benzyl)-[3-(3-trifluoromethyl-phenyl)-propyl]-amine	S2-C	350.4 (M+H) ⁺
S9-C45	(4-tert-Butyl-benzyl)-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-amine	S1-C	330.4 (M+H) ⁺
S9-C46	(4-tert-Butyl-benzyl)-[3-(3-chloro-phenyl)-propyl]-amine	S2-C	316.1 (M+H) ⁺
S9-C47	(4-tert-Butyl-benzyl)-[3-(4-chloro-phenyl)-propyl]-amine	S2-C	316.1 (M+H) ⁺
S9-C48	[2-(4-Benzoyloxy-3-tert-butyl-phenyl)-ethyl]-(4-tert-butyl-benzyl)-amine	S2-C	430.5 (M+H) ⁺
S9-C49	[2-(3-Bromo-4-fluoro-phenyl)-ethyl]-(4-tert-butyl-benzyl)-amine	S1-C	366.1 (M+H) ⁺

*: Prepared in analogy to example

Example S10-C: Preparation of (4-tert-butyl-benzyl)-[2-(3-ethyl-phenyl)-ethyl]-amine

a) Preparation of [2-(3-bromo-phenyl)-ethyl]-(4-tert-butyl-benzyl)-carbamic acid tert-butyl ester:

To a solution of [2-(3-bromo-phenyl)-ethyl]-(4-tert-butyl-benzyl)-amine (3544 mg, 10.23 mmol) in DCM (30 ml) was added di-tert-butyl-dicarbonate (2507 mg, 11.3 mmol) at 0°C. The reaction mixture was stirred for 30 min at 0°C and then at RT over night. Saturated NH₄Cl solution was added and the mixture was extracted with DCM. The combined organic extracts were washed with 10% KHCO₃ solution and brine and were dried (Na₂SO₄). After evaporation of the solvent the crude title compound (4722 mg) was obtained as a colorless oil. MS (ISP) 446.4 (M+H)⁺.

b) Preparation of (4-tert-butyl-benzyl)-[2-(3-trimethylsilanylethynyl-phenyl)-ethyl]-carbamic acid tert-butyl ester:

A mixture of the crude [2-(3-bromo-phenyl)-ethyl]-(4-tert-butyl-benzyl)-carbamic acid tert-butyl ester (515 mg, 1.154 mmol), bis(triphenylphosphine)palladium(II)chloride (32 mg, 0.0461 mmol), CuI (11 mg, 0.0577 mmol) and (trimethylsilyl)acetylene (251 µl, 1.73 mmol) in triethylamine (3.4 ml) was heated in a sealed tube at 105°C over night. The mixture was then cooled to RT, diluted with sat. NaHCO₃-solution and extracted three times with ethyl acetate. The combined ethyl acetate layers were then washed with water and brine and were dried (Na₂SO₄) and evaporated. The remaining residue was purified by chromatography (heptane/EtOAc 100:0 to 95:5) to obtain the title compound as a yellow gum (441 mg, 82%). MS (ISP) 464.4 (M+H)⁺.

c) Preparation of (4-tert-butyl-benzyl)-[2-(3-ethynyl-phenyl)-ethyl]-carbamic acid tert-butyl ester:

To a solution of (4-tert-butyl-benzyl)-[2-(3-trimethylsilanylethynyl-phenyl)-ethyl]-carbamic acid tert-butyl ester (440 mg, 0.949 mmol) in THF (7.6 ml) was added a 1 molar solution of TBAF in THF (949 µl, 0.949 mmol) at -78°C. After 15 min at -78°C the solution was allowed to warm to 0°C for 30 min. Then brine was added and the mixture was extracted with ether. The combined ether layers were dried (Na₂SO₄) and evaporated and the remaining residue was purified by chromatography (pentane/ether 100:0 to 90:10) to obtain the title compound as a colorless oil (314 mg, 84%). MS (ISP) 392.3 (M+H)⁺.

d) Preparation of (4-tert-butyl-benzyl)-[2-(3-ethyl-phenyl)-ethyl]-carbamic acid tert-butyl ester:

A solution of (4-tert-butyl-benzyl)-[2-(3-ethynyl-phenyl)-ethyl]-carbamic acid tert-butyl ester (149 mg, 0.381 mmol) in methanol (12 ml) was stirred at RT under an atmosphere of

hydrogen in the presence of a catalytic amount of palladium on charcoal (5%) for 2 days. The reaction mixture was then filtered and evaporated and the remaining residue was purified by chromatography (heptane/EtOAc 100:0 to 95:5) to obtain the title compound as a colorless oil (73 mg, 48%). MS (ISP) 396.4 (M+H)⁺.

5 e) Preparation of (4-*tert*-butyl-benzyl)-[2-(3-ethyl-phenyl)-ethyl]-amine:

To a solution of (4-*tert*-butyl-benzyl)-[2-(3-ethyl-phenyl)-ethyl]-carbamic acid *tert*-butyl ester 66 mg, 0.166 mmol) in DCM (1 ml) was added trifluoroacetic acid (128 μ l, 1.668 mmol) at 0°C. The reaction mixture was allowed to warm to RT and was stirred over night. The mixture was then basified with 1 N NaOH and extracted with DCM. The combined
10 extracts were dried (Na₂SO₄) and evaporated to obtain the title compound as a colorless gum (45 mg, 92%). MS (ISP) 296.5 (M+H)⁺.

Example S11-C: Preparation of (4-*tert*-butylbenzyl)-[2-(4-chloro-3-cyclopropylphenyl)-ethyl]-amine and (4-*tert*-butylbenzyl)-[2-(3,4-dicyclopropylphenyl)-ethyl]-amine

15 The title compounds were synthesized in analogy to 3-cyclopropyl-4-fluorophenylamine (step a, example S8-C) using [2-(3-bromo-4-chlorophenyl)-ethyl]-(4-*tert*-butylbenzyl)-amine (128 mg, 0.34 mmol) and cyclopropyl boronic acid (72 mg, 0.84 mmol). The residue was purified by flash column chromatography to give an unseperable 1:4 mixture of products (4-*tert*-butylbenzyl)-[2-(4-chloro-3-cyclopropylphenyl)-ethyl]-amine (13 mg,
20 11%), MS (ISP) 342.2 (M+H)⁺ and (4-*tert*-butylbenzyl)-[2-(3,4-dicyclopropylphenyl)-ethyl]-amine (55 mg, 47%), MS (ISP) 348.4 (M+H)⁺ which was reacted on without further purification.

Example S12-C: Preparation of (4-*tert*-butylbenzyl)-[2-(4-chloro-3-isopropylphenyl)-ethyl]-amine

25 a) Preparation of 2-(5-bromo-2-chlorophenyl)-propan-2-ol:

To a solution of 5-bromo-2-chlorobenzoic acid methyl ester (1 g, 4 mmol, 1eq) in THF (20 ml) at -78°C was added a 3M solution of methyl magnesiumbromide (4 ml, 12 mmol, 3eq) in THF dropwise. The reaction mixture was then warmed to RT and stirred overnight. The mixture was poured into sat. ammonium chloride solution and extracted with ether. The
30 organic layers were combined, washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo* to give a residue which was purified by flash column chromatography (0 to 20% ether in pentane) to give the desired product as a colorless oil (980 mg, 98%).

b) Preparation of 4-bromo-1-chloro-2-isopropenylbenzene:

To a solution of 2-(5-bromo-2-chlorophenyl)-propan-2-ol (500 mg, 2 mmol, 1eq) in toluene (5 ml) was added a catalytic amount of *p*-toluenesulfonic acid (38 mg, 0.2 mmol, 0.1eq) and the solution was refluxed under a Dean-Stark H₂O separator overnight. The reaction mixture was allowed to cool to RT and was diluted with ether. The mixture was washed with sat. NaHCO₃-solution and brine, dried (MgSO₄), filtered and concentrated *in vacuo* to give the desired product (357 mg, 77%) as a colorless oil which did not require further purification.

c) Preparation of 4-bromo-1-chloro-2-isopropenylbenzene:

- 10 A mixture of 4-bromo-1-chloro-2-isopropenylbenzene (357 mg, 1.54 mmol, 1eq) and PtO₂ (35 mg, 0.15 mmol, 0.1eq) in 4 ml toluene was stirred under an atmosphere of hydrogen at RT overnight. The reaction mixture was then filtered through celite® and the filtrate was evaporated to dryness to give the desired product (260 mg, 72%). ¹H NMR (CDCl₃, 300 MHz): 7.39 (d, J=2 Hz, 1H), 7.26-7.16 (m, 2H), 3.35 (sept, J=7 Hz, 1H), 1.23 (d, J=7 Hz, 15 6H).

d) Preparation of (4-*tert*-butylbenzyl)-[2-(4-chloro-3-isopropylphenyl)-ethyl]-amine:

- The title compound was synthesized in analogy to example S6-C using 4-bromo-1-chloro-2-isopropylbenzene (120 mg, 0.51 mmol), and 3-(4-*tert*-butylbenzyl)-[1,2,3]oxathiazolidine 2, 2-dioxide (138 mg, 0.51 mmol). The residue was purified by flash column chromatography to give the desired product (74 mg, 42%) as a light yellow oil. MS (ISP) 344.3 (M+H)⁺.
- 20

Acids (Compounds of formula II):

Example S1-D: Preparation of 2-chloro-6-trifluoromethyl-isonicotinic acid

a) Preparation of 6-chloro-3-iodo-2-trifluoromethyl-pyridine:

- 25 To a stirred solution of 7.1 ml of *n*-BuLi (1.6M in hexane, 11.3 mmol) in 7 ml THF under argon at -73°C were added 1.6 ml of diisopropylamine (11.3 mmol) in 3 ml THF within 8 min. After 10 min stirring at the same temperature a solution of 1 g of 2-chloro-6-(trifluoromethyl)-pyridine (5.51 mmol) in 5 ml THF was added within 15 min (temperature between -76 and -75°C). The dark brown solution was stirred at -75°C for 1 h 15 min.
- 30 Finally a solution of 1.4 g of iodine (5.51 mmol) in 10 ml THF was added at -75°C over 25 min. After additional 45 min stirring at the same temperature 12 ml 2M aqueous HCl were added within 2 min (temperature raised from -78 to -50°C. The cooling device was then removed, the reaction mixture diluted with diethylether. After separation of the organic

phase, the aqueous phase was reextracted with diethylether. The combined organic phases were successively washed with 10 ml 1M sodiumthiosulfate, saturated NaHCO_3 and brine, dried over magnesium sulfate, filtered off and concentrated in vacuo to yield 1.54 (69 %) of 6-chloro-3-iodo-2-trifluoromethyl-pyridine as a brown semisolid residue. MS: 307.0

5 b) Preparation of 2-chloro-4-iodo-6-trifluoromethyl-pyridine:

To a stirred solution of 3.05 ml of n-BuLi (1.6 M in hexane, 4.88 mmol) under argon at -75°C was added 0.69 ml of diisopropylamine (4.88 mmol) in 2.5 ml THF over 5 min (temperature between -72 and -75°C). After 10 min at -75°C a solution of 1.5 g of 6-chloro-3-iodo-2-trifluoromethyl-pyridine (4.88 mmol) in 3.5 ml THF was added drop-
10 wise over 20 min at the same temperature. After 1.5 hours stirring at -75°C, 6 ml 2M aqueous HCl were added (temperature was allowed to raise to RT). The mixture was then diluted with water, extracted with diethylether and the combined organic phases were successively washed with saturated NaHCO_3 solution and brine, dried over magnesium sulfate, filtered off and concentrated in vacuo. The residue was purified by silicagel chro-
15 matography (eluent: heptane / AcOEt 95:5) leading to 1.145 g (69 %) of 2-chloro-4-iodo-6-trifluoromethyl-pyridine as a white powder. MS: 307.0

c) Preparation of 2-chloro-6-trifluoromethyl-isonicotinic acid:

To a stirred solution of 1.1 g of 2-chloro-4-iodo-6-trifluoromethyl-pyridine (3.58 mmol) in 15 ml THF under argon at -75°C, were added 2.2 ml of n-BuLi (1.6 M in hexane) within
20 15 min (temperature kept between -72°C and -75°C). After 5 additional min stirring at -75°C, the reaction mixture was poured on an excess of freshly crushed dry ice and stirred until RT was reached. The reaction mixture was then concentrated in vacuo, the remaining residue treated with 2M aqueous HCl and the resulting mixture was extracted with diethylether. The combined organic phases were washed with water, and then extracted with
25 saturated NaHCO_3 solution. The aqueous phase was then acidified with concentrated HCl, extracted twice with diethylether and the combined organic phases were washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. The remaining residue was recrystallized from 12 ml hot n-hexane, leading to 0.459 g (56 %) of 2-chloro-6-trifluoromethyl-isonicotinic acid as an off-white solid. MS: 224.0 (M-H)⁻.

30 Example S2-D: Preparation of 3-chloro-4-fluoro-5-trifluoromethyl-benzoic acid

To a stirred solution of 2.03 ml of sec-BuLi (1.3M in cyclohexane, 2.64 mmol) and 0.4 ml of TMEDA under argon at -90°C was added a solution of 0.25 g of 4-fluoro-3-trifluoromethyl-benzoic acid (1.2 mmol) in 8 ml THF over 20 min (temperature kept between -

92°C and -88°C). After 30 min stirring at the same temperature, the initially light orange suspension turned brown. A solution of 1.14 g of hexachloroethane (4.82 mmol) in 10 ml THF was then added within 2 min (temperature raised to -62°C). The reaction mixture was then left to warm slowly to RT (1 hour) and treated carefully with 2 ml water. The reaction
5 mixture was then concentrated in vacuo, diluted with water and extracted with diethyl-ether. The aqueous phase was then acidified with concentrated HCl and extracted twice with ethylacetate. The combined ethylacetate phases were subsequently washed with water (3x) and brine (1x), dried over magnesium sulfate, filtered and concentrated in vacuo to yield 0.28 g of a residue which was purified by silicagel chromatography (eluent heptane / AcOEt
10 90:10 to 75:25) to yield 22 mg of 3-chloro-4-fluoro-5-trifluoromethyl-benzoic acid as a light yellow solid. MS: 241.1 (M-H)⁻.

Example S3-D: Preparation of 3-chloro-5-cyclopropylbenzoic acid:

To a solution of 1-bromo-3-chloro-5-cyclopropylbenzene (300 mg, 1.30 mmol) at -78°C in THF (5 ml) was added *n*BuLi (890 µl, 1.6M solution in hexane, 1.43 mmol) dropwise. The
15 resulting solution was stirred at -78°C for 10 min after which solid carbon dioxide was added and the reaction mixture was warmed to RT over 3 hours. The reaction mixture was quenched with water and then extracted with ether. The aqueous phase was then made acidic with 1N HCl and then extracted with ethyl acetate. The organic phases were combined, washed with brine, dried (MgSO₄), filtered and concentrated in *vacuo* to give the
20 desired product 3-chloro-5-cyclopropylbenzoic acid (178 mg, 70%) which did not require further purification. MS (ISP) 195.1 (M-H)⁻.

Example S4-D: Preparation of 6-chloro-4-trifluoromethyl-pyridine-2-carboxylic acid:

To a solution of 300 mg of 2-chloro-6-methyl-4-(trifluoromethyl)-pyridine (1.49 mmol) in pyridine (5 ml) was added a solution of 1.61 g of tetrabutylammonium permanganate
25 (4.46 mmol) in pyridine (4.5 ml) and the reaction mixture was stirred at 80°C for 3 h. The reaction mixture was then poured into a mixture of water and ice and then NaHSO₃ solution (40% in water) was added until the color turned light yellow. The mixture was then acidified by addition of 2N HCl and extracted with ethyl acetate. The combined organic layers were then washed with 1N HCl and brine, dried (Na₂SO₄), filtered and concentrated.
30 The remaining residue was purified by chromatography (DCM / MeOH 100:0 to 90:10) to yield 224 mg (67%) of a gray liquid. MS (ISP) 224.3 (M-H)⁻.

Example S5-D: Preparation of 6-Methyl-2-trifluoromethyl-pyrimidine-4-carboxylic acid

- a) Preparation of 6-methyl-2-trifluoromethyl-pyrimidine-4-carboxylic acid ethyl ester:
2.241 g (20 mmol) of 2,2,2-trifluoro-acetamidine were dissolved in 80 ml ethanol and treated with 3.163 g (20 mmol) of 2,4-dioxo-pentanoic acid ethyl ester. The resulting solution was cooled to 0-5 °C and treated with 120 ml of HCl-saturated ethanol. The reaction mixture was allowed to warm-up to RT and stirred for additional 3 hours. The mixture was then added dropwise under cooling to 800 ml saturated NaHCO₃ solution. The resulting mixture was then extracted twice with 300 ml DCM and the combined organic phases were dried over magnesium sulfate, filtered and concentrated in vacuo to yield 3.1 g of a yellow oil. This residue was then purified by silicagel chromatography (eluent: heptane / ethyl acetate 100:0 to 30:70) leading to a colorless oil which crystallized spontaneously, leading to 1.3 g of 6-methyl-2-trifluoromethyl-pyrimidine-4-carboxylic acid ethyl ester.
- b) Preparation of 6-methyl-2-trifluoromethyl-pyrimidine-4-carboxylic acid:
1.3 g (5.551 mmol) of 6-methyl-2-trifluoromethyl-pyrimidine-4-carboxylic acid ethyl ester were dissolved in 30 ml dioxane and treated with 11.1 ml (11.1 mmol) 1 N NaOH and stirred for 2 hours at RT. The reaction mixture was then treated with 11.1 ml (11.1 mmol) 1 N HCl and concentrated in vacuo. The resulting solid residue was then suspended in DCM-methanol, filtered-off, washed with additional DCM-methanol and the combined organic phases were then concentrated in vacuo, to yield 1.1 g (96 %) of 6-methyl-2-trifluoromethyl-pyrimidine-4-carboxylic acid. MS: 205.1 (M-H)⁻.

Compounds of formula I:

Example 1: Preparation of N-(4-tert-butyl-benzyl)-3-chloro-N-[2-(4-chloro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide (B1)

To a solution of 50 mg of 3-chloro-2-fluoro-5-trifluoromethyl-benzoic acid (0.206 mmol) and 68 mg (0.225 mmol) of (4-tert-butylbenzyl)-[2-(4-chlorophenyl)-ethyl]-amine in 3 ml of DMF were added 117 mg of HBTU (0.31 mmol) and 0.063 ml (0.62 mmol) of 4-methylmorpholine. After stirring the reaction mixture over night at RT it was poured on a mixture of 15 ml of brine and 15 ml of water and extracted with ethyl acetate. The combined organic phases were washed with brine, dried with magnesium sulfate, filtered and concentrated in *vacuo*. The residue was purified by column chromatography (silica gel; heptane/-EtOAc 95:5) to give 76 mg (70 %) of a light yellow amorphous material. MS (ISP) 526.0 (M+H)⁺.

In analogy to example 1:

Example	Name	MS
B2	N-(4-tert-Butyl-benzyl)-N-[2-(3,4-dichloro-phenyl)-ethyl]-2-fluoro-nicotinamide	459.3 [ISP (M+H)+]
B3	N-(4-tert-Butyl-benzyl)-4-chloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-nicotinamide	475.2 [ISP (M+H)+]
B4	N-(4-tert-Butyl-benzyl)-2,5-dichloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-nicotinamide	509 [ISP (M+H)+]
B5	5-Bromo-N-(4-tert-butyl-benzyl)-2-chloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-nicotinamide	553 [ISP (M+H)+]
B6	N-(4-tert-Butyl-benzyl)-2-chloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-5-fluoro-nicotinamide	493.3 [ISP (M+H)+]
B7	N-(4-tert-Butyl-benzyl)-2-chloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-5-trifluoromethyl-isonicotinamide	543.1 [ISP (M+H)+]
B8	N-(4-tert-Butoxy-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	576.1 [ISP (M+H)+]
B9	N-(4-tert-Butyl-benzyl)-2,6-dichloro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-isonicotinamide	509.3 [ISP (M+H)+]

B10	N-(4-tert-Butyl-benzyl)-2,6-dichloro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-isonicotinamide	527 [ISP (M+H)+]
B11	N-(4-tert-Butyl-benzyl)-2,6-dichloro-N-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-isonicotinamide	527 [ISP (M+H)+]
B12	N-(4-tert-Butyl-benzyl)-2-chloro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-6-trifluoromethyl-isonicotinamide	561.3 [ISP (M+H)+]
B13	N-(4-tert-Butyl-benzyl)-2,6-dichloro-N-[2-(3-chloro-5-trifluoromethyl-phenyl)-ethyl]-isonicotinamide	543.1 [ISP (M+H) ⁺]
B14	N-(4-tert-Butyl-benzyl)-2-chloro-N-[2-(3-chloro-5-trifluoromethyl-phenyl)-ethyl]-6-trifluoromethyl-isonicotinamide	577.2 [ISP (M+H) ⁺]
B15	N-(4-tert-Butyl-benzyl)-2-chloro-6-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-isonicotinamide	543.1 [ISP (M+H) ⁺]
B16	N-(4-tert-Butyl-benzyl)-2-chloro-N-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-6-trifluoromethyl-isonicotinamide	561.3 [ISP (M+H) ⁺]
B17	N-(4-tert-Butyl-benzyl)-2,6-dichloro-N-[2-(4-chloro-3-fluoro-phenyl)-ethyl]-isonicotinamide	493.1 [ISP (M+H) ⁺]
B18	N-(4-tert-Butyl-benzyl)-2-chloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-6-trifluoromethyl-isonicotinamide	543.2 [ISP (M+H) ⁺]
B19	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(2-chloro-pyridin-4-yl)-ethyl]-5-trifluoromethyl-benzamide	509.4 [ISP (M+H) ⁺]
B20	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(2-chloro-pyridin-4-yl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	527.1 [ISP (M+H) ⁺]
B21	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-3-trifluoromethyl-pyrazol-1-yl)-ethyl]-5-trifluoromethyl-benzamide	566.2 [ISP (M+H) ⁺]
B22	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-3-trifluoromethyl-pyrazol-1-yl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	584.1 [ISP (M+H) ⁺]

B23	N-(4-tert-Butyl-benzyl)-3-chloro-5-trifluoromethyl-N-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-benzamide	543.1 [ISP (M+H) ⁺]
B24	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-N-[2-(6-trifluoromethyl-pyridin-2-yl)-ethyl]-benzamide	561 [ISP (M+H) ⁺]
B25	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-N-phenethyl-5-trifluoromethyl-benzamide	492 [ISP (M+H) ⁺]
B26	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3,4-dichlorophenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	559.8 [ISP (M+H) ⁺]
B27	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-N-(2-p-tolyl-ethyl)-5-trifluoromethyl-benzamide	506 [ISP (M+H) ⁺]
B28	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	510.3 [ISP (M+H) ⁺]
B29	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-chlorophenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	526.1 [ISP (M+H) ⁺]
B30	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	560.3 [ISP (M+H) ⁺]
B31	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3,4-dichlorophenyl)-ethyl]-2-fluoro-benzamide	492.2 [ISP (M+H) ⁺]
B32	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	491.3 [ISP (M+H) ⁺]
B33	N-(4-tert-Butyl-benzyl)-3,5-bis-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	576.1 [ISP (M+H) ⁺]
B34	N-(4-tert-Butyl-benzyl)-2,6-difluoro-3-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	544.3 [ISP (M+H) ⁺]
B35	N-(4-tert-Butyl-benzyl)-2,4,6-trifluoro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	494.5 [ISP (M+H) ⁺]
B36	N-(4-tert-Butyl-benzyl)-2-fluoro-5-iodo-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	584.2 [ISP (M+H) ⁺]
B37	N-(4-tert-Butyl-benzyl)-5-chloro-2,3,4-trifluoro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	528.3 [ISP (M+H) ⁺]

B38	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-5-hydroxy-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	508.5 [ISP (M+H) ⁺]
B39	N-(4-tert-Butyl-benzyl)-5-chloro-2-fluoro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	492.1 [ISP (M+H) ⁺]

B40	N-(4-tert-Butyl-benzyl)-3,5-dichloro-2-hydroxy-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	523.2 [ISP (M+H) ⁺]
B41	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-N-[2-(3-trifluoromethoxy-phenyl)-ethyl]-5-trifluoromethyl-benzamide	576.1 [ISP (M+H) ⁺]
B42	N-(4-tert-Butyl-benzyl)-2,5-dichloro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	508.3 [ISP (M+H) ⁺]
B43	N-(4-tert-Butyl-benzyl)-5-chloro-2-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	542.2 [ISP (M+H) ⁺]
B44	N-(4-tert-Butyl-benzyl)-3-chloro-5-fluoro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	492.1 [ISP (M+H) ⁺]
B45	N-(4-tert-Butyl-benzyl)-3,5-dichloro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	508.3 [ISP (M+H) ⁺]
B46	N-(4-tert-Butyl-benzyl)-3-fluoro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	526.3 [ISP (M+H) ⁺]
B47	N-(4-tert-Butyl-benzyl)-2,3-dichloro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	508.3 [ISP (M+H) ⁺]
B48	N-(4-tert-Butyl-benzyl)-3-chloro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	542.2 [ISP (M+H) ⁺]
B49	N-(4-tert-Butyl-benzyl)-3,5-dichloro-N-[2-(3-trifluoromethoxy-phenyl)-ethyl]-benzamide	524.1 [ISP (M+H) ⁺]
B50	N-(4-tert-Butyl-benzyl)-3,5-dichloro-N-[2-(4-fluoro-phenyl)-ethyl]-benzamide	458.2 [ISP (M+H) ⁺]
B51	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-trifluoromethoxy-phenyl)-ethyl]-5-trifluoromethyl-benzamide	558.2 [ISP (M+H) ⁺]
B52	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	492.1 [ISP (M+H) ⁺]
B53	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	508.3 [ISP (M+H) ⁺]

B54	N-(4-tert-Butyl-benzyl)-3-fluoro-N-[2-(3-trifluoromethoxy-phenyl)-ethyl]-5-trifluoromethyl-benzamide	542.2 [ISP (M+H) ⁺]
B55	N-(4-tert-Butyl-benzyl)-N-[2-(4-chloro-phenyl)-ethyl]-3-fluoro-5-trifluoromethyl-benzamide	492.1 [ISP (M+H) ⁺]
B56	N-(4-tert-Butyl-benzyl)-3,5-dimethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	468.5 [ISP (M+H) ⁺]

B57	N-(4-tert-Butyl-benzyl)-2-fluoro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	526.3 [ISP (M+H) ⁺]
B58	N-(4-tert-Butyl-benzyl)-3-chloro-4-fluoro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	560.3 [ISP (M+H) ⁺]
B59	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide	560.3 [ISP (M+H) ⁺]
B60	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide	560.3 [ISP (M+H) ⁺]
B61	N-(4-tert-Butyl-benzyl)-4-chloro-3-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	542.1 [ISP (M+H) ⁺]
B62	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	542.2 [ISP (M+H) ⁺]
B63	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide	578.3 [ISP (M+H) ⁺]
B64	N-(4-tert-Butyl-benzyl)-3-fluoro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide	544.3 [ISP (M+H) ⁺]
B65	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-N-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide	578.2 [ISP (M+H) ⁺]
B66	N-(4-tert-Butyl-benzyl)-3-chloro-N-(3-phenyl-propyl)-5-trifluoromethyl-benzamide	488.1 [ISP (M+H) ⁺]
B67	N-(4-tert-Butyl-benzyl)-3,5-dichloro-4-fluoro-N-[2-	526.2 [ISP (M+H) ⁺]

	(3-trifluoromethyl-phenyl)-ethyl]-benzamide	
B68	N-(4-tert-Butyl-benzyl)-3,5-dichloro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-benzamide	526 [ISP (M+H) ⁺]
B69	N-(4-tert-Butyl-benzyl)-3,5-dichloro-N-[2-(4-fluoro-3-trifluoromethyl-phenyl)-ethyl]-benzamide	526 [ISP (M+H) ⁺]
B70	N-(4-tert-Butyl-benzyl)-3,5-dichloro-4-fluoro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-benzamide	544.1 [ISP (M+H) ⁺]
B71	N-(4-tert-Butyl-benzyl)-3,5-dichloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-benzamide	508.2 [ISP (M+H) ⁺]
B72	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-cyclopropyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide	514.2 [ISP (M+H) ⁺]
B73	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-chloro-5-cyclopropyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide	548.1 [ISP (M+H) ⁺]
B74	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-chloro-5-cyclopropyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	566.2 [ISP (M+H) ⁺]
B75	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-cyclopropyl-5-fluoro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	550.2 [ISP (M+H) ⁺]
B76	N-(4-tert-Butyl-benzyl)-3-chloro-5-cyclopropyl-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-benzamide	532.1 [ISP (M+H) ⁺]
B77	N-(4-tert-Butyl-benzyl)-3-chloro-5-cyclopropyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	514.2 [ISP (M+H) ⁺]
B78	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-chloro-5-trifluoromethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	594.2 [ISP (M+H) ⁺]
B79	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-chloro-5-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide	576.3 [ISP (M+H) ⁺]
B80	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-3-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	526 [ISP (M+H) ⁺]
B81	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-2-fluoro-N-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-	638.1 [ISP (M+H) ⁺]

	benzyl]-5-trifluoromethyl-benzamide	
B82	3-Chloro-2-fluoro-N-[2-(4-fluoro-phenyl)-ethyl]-N-(4-pentafluoroethyl-benzyl)-5-trifluoromethyl-benzamide	572.1 [ISP (M+H) ⁺]
B83	N-(4-tert-Butyl-benzyl)-2-chloro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	542.3 [ISP (M+H) ⁺]
B84	N-(4-tert-Butyl-benzyl)-3,5-difluoro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	476 [ISP (M+H) ⁺]
B85	N-(4-tert-Butyl-benzyl)-3,5-dichloro-N-[2-(4-chloro-phenyl)-ethyl]-benzamide	474 [ISP (M+H) ⁺]

B86	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-N-[2-(4-trifluoromethyl-phenyl)-ethyl]-benzamide	560.3 [ISP (M+H) ⁺]
B87	N-(4-tert-Butyl-benzyl)-3-fluoro-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	476 [ISP (M+H) ⁺]
B88	3-Chloro-N-(4-cyclobutyl-benzyl)-2-fluoro-N-[2-(3-trifluoromethoxy-phenyl)-ethyl]-5-trifluoromethyl-benzamide	574.3 [ISP (M+H) ⁺]
B89	3-Chloro-N-(4-cyclobutyl-benzyl)-N-[2-(3-trifluoromethoxy-phenyl)-ethyl]-5-trifluoromethyl-benzamide	556.2 [ISP (M+H) ⁺]
B90	N-(4-Cyclobutyl-benzyl)-3-fluoro-N-[2-(3-trifluoromethoxy-phenyl)-ethyl]-5-trifluoromethyl-benzamide	540.3 [ISP (M+H) ⁺]
B91	3,5-Dichloro-N-(4-cyclobutyl-benzyl)-N-[2-(3-trifluoromethoxy-phenyl)-ethyl]-benzamide	552.3 [ISP (M+H) ⁺]
B92	3-Chloro-N-(4-cyclobutyl-benzyl)-2-fluoro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	558 [ISP (M+H) ⁺]
B93	3-Chloro-N-(4-cyclobutyl-benzyl)-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	540.2 [ISP (M+H) ⁺]
B94	N-(4-Cyclobutyl-benzyl)-3-fluoro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	524.2 [ISP (M+H) ⁺]
B95	3,5-Dichloro-N-(4-cyclobutyl-benzyl)-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	506.1 [ISP (M+H) ⁺]

B96	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-N-(4-cyclobutyl-benzyl)-2-fluoro-5-trifluoromethyl-benzamide	524.2 [ISP (M+H) ⁺]
B97	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-N-(4-cyclobutyl-benzyl)-5-trifluoromethyl-benzamide	506.2 [ISP (M+H) ⁺]
B98	N-[2-(4-Chloro-phenyl)-ethyl]-N-(4-cyclobutyl-benzyl)-3-fluoro-5-trifluoromethyl-benzamide	490.3 [ISP (M+H) ⁺]
B99	3,5-Dichloro-N-[2-(4-chloro-phenyl)-ethyl]-N-(4-cyclobutyl-benzyl)-benzamide	472 [ISP (M+H) ⁺]
B100	3-Chloro-N-(4-cyclobutyl-benzyl)-2-fluoro-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	508.4 [ISP (M+H) ⁺]
B101	3-Chloro-N-(4-cyclobutyl-benzyl)-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	490.3 [ISP (M+H) ⁺]

B102	N-(4-Cyclobutyl-benzyl)-3-fluoro-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	474.1 [ISP (M+H) ⁺]
B103	3,5-Dichloro-N-(4-cyclobutyl-benzyl)-N-[2-(4-fluoro-phenyl)-ethyl]-benzamide	456.2 [ISP (M+H) ⁺]
B104	3,5-Dichloro-N-[2-(4-chloro-phenyl)-ethyl]-N-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-benzyl]-benzamide	586.1 [ISP (M+H) ⁺]
B105	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-N-[4-(1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl)-benzyl]-5-trifluoromethyl-benzamide	620.2 [ISP (M+H) ⁺]
B106	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-N-[4-(1,1-dimethyl-propyl)-benzyl]-2-fluoro-5-trifluoromethyl-benzamide	540.3 [ISP (M+H) ⁺]
B107	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-N-[4-(1,1-dimethyl-propyl)-benzyl]-5-trifluoromethyl-benzamide	522.2 [ISP (M+H) ⁺]
B108	3,5-Dichloro-N-[2-(4-chloro-phenyl)-ethyl]-N-[4-(1,1-dimethyl-propyl)-benzyl]-benzamide	488.1 [ISP (M+H) ⁺]
B109	3-Chloro-2-fluoro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-N-(4-trimethylsilanyl-benzyl)-benzamide	576.4 [ISP (M+H) ⁺]

B110	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-N-(4-trimethylsilyl-benzyl)-benzamide	542.2 [ISP (M+H) ⁺]
B111	3-Chloro-2-fluoro-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-N-(4-trimethylsilyl-benzyl)-benzamide	526.2 [ISP (M+H) ⁺]
B112	3-Chloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-N-(4-trimethylsilyl-benzyl)-benzamide	576.3 [ISP (M+H) ⁺]
B113	3-Chloro-2-fluoro-N-[2-(3-trifluoromethoxy-phenyl)-ethyl]-5-trifluoromethyl-N-(4-trimethylsilyl-benzyl)-benzamide	592.3 [ISP (M+H) ⁺]
B114	3-Chloro-2-fluoro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-N-(4-trimethylsilyl-benzyl)-benzamide	508.4 [ISP (M+H) ⁺]

B115	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-2-fluoro-N-(4-trimethylsilyl-benzyl)-benzamide	474.2 [ISP (M+H) ⁺]
B116	3-Chloro-2-fluoro-N-[2-(4-fluoro-phenyl)-ethyl]-N-(4-trimethylsilyl-benzyl)-benzamide	458.4 [ISP (M+H) ⁺]
B117	3-Chloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-2-fluoro-N-(4-trimethylsilyl-benzyl)-benzamide	508.3 [ISP (M+H) ⁺]
B118	5-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-2-fluoro-N-(4-trimethylsilyl-benzyl)-benzamide	474.2 [ISP (M+H) ⁺]
B119	3,5-Dichloro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-N-(4-trimethylsilyl-benzyl)-benzamide	524.4 [ISP (M+H) ⁺]
B120	3,5-Dichloro-N-[2-(4-chloro-phenyl)-ethyl]-N-(4-trimethylsilyl-benzyl)-benzamide	490.2 [ISP (M+H) ⁺]
B121	3,5-Dichloro-N-[2-(4-fluoro-phenyl)-ethyl]-N-(4-trimethylsilyl-benzyl)-benzamide	474.2 [ISP (M+H) ⁺]
B122	3,5-Dichloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-N-(4-trimethylsilyl-benzyl)-benzamide	526.2 [ISP (M+H) ⁺]
B123	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-5-trifluoromethyl-N-(4-trimethylsilyl-benzyl)-benzamide	524.4 [ISP (M+H) ⁺]
B124	3-Chloro-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoro-	508.4 [ISP (M+H) ⁺]

	methyl-N-(4-trimethylsilanyl-benzyl)-benzamide	
B125	3-Chloro-N-[2-(3,4-dichloro-phenyl)-ethyl]-5-trifluoromethyl-N-(4-trimethylsilanyl-benzyl)-benzamide	558.1 [ISP (M+H) ⁺]
B126	3-Chloro-N-[4-(1,1-dimethyl-propyl)-benzyl]-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	556.2 [ISP (M+H) ⁺]
B127	3-Chloro-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-N-(4-trimethylsilanyl-benzyl)-benzamide	558 [ISP (M+H) ⁺]
B128	3-Chloro-N-(4-cyclopropyl-benzyl)-N-[2-(3,4-dichloro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	526.1 [ISP (M+H) ⁺]
B129	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-5-trifluoromethyl-N-(4-trifluoromethyl-benzyl)-benzamide	520 [ISP (M+H) ⁺]
B130	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-N-(4-trifluoromethoxy-benzyl)-5-trifluoromethyl-benzamide	536 [ISP (M+H) ⁺]

B131	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-N-[4-(1-fluoro-cyclobutyl)-benzyl]-5-trifluoromethyl-benzamide	524.1 [ISP (M+H) ⁺]
B132	3-Chloro-N-[4-(1-fluoro-cyclobutyl)-benzyl]-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	508.1 [ISP (M+H) ⁺]
B133	3-Chloro-N-[2-(3-chloro-phenyl)-ethyl]-N-[4-(1-fluoro-cyclobutyl)-benzyl]-5-trifluoromethyl-benzamide	524.1 [ISP (M+H) ⁺]
B134	3-Chloro-N-[4-(1-fluoro-cyclobutyl)-benzyl]-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	558 [ISP (M+H) ⁺]
B135	3-Chloro-N-[2-(4-chloro-phenyl)-ethyl]-2-fluoro-N-[4-(1-fluoro-cyclobutyl)-benzyl]-5-trifluoromethyl-benzamide	542.2 [ISP (M+H) ⁺]
B136	3-Chloro-2-fluoro-N-[4-(1-fluoro-cyclobutyl)-benzyl]-N-[2-(4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	526.2 [ISP (M+H) ⁺]

B137	3-Chloro-N-[2-(3-chloro-phenyl)-ethyl]-2-fluoro-N-[4-(1-fluoro-cyclobutyl)-benzyl]-5-trifluoromethyl-benzamide	542.2 [ISP (M+H) ⁺]
B138	3-Chloro-2-fluoro-N-[4-(1-fluoro-cyclobutyl)-benzyl]-5-trifluoromethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	576.3 [ISP (M+H) ⁺]
B139	N-(4-tert-Butyl-benzyl)-2-chloro-N-[2-(3,5-dichloro-phenyl)-ethyl]-6-trifluoromethyl-isonicotinamide	542 [EI (M) ⁺]
B140	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3,5-dichloro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	541 [EI (M) ⁺]
B141	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3,5-dichloro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	560.2 [ISP (M+H) ⁺]
B142	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	593.1 [EI (M) ⁺]
B143	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide	575.1 [EI (M) ⁺]

B144	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-chloro-5-fluoro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	544.1 [ISP (M+H) ⁺]
B145	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-chloro-5-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	526.2 [ISP (M+H) ⁺]
B146	N-(4-tert-Butyl-benzyl)-2-chloro-N-[2-(3-chloro-4-fluoro-phenyl)-ethyl]-6-trifluoromethyl-isonicotinamide	527.0 [ISP (M+H) ⁺]
B147	N-(4-tert-Butyl-benzyl)-2-chloro-N-[2-(4-chloro-3-trifluoromethyl-phenyl)-ethyl]-6-trifluoromethyl-isonicotinamide	576.2 [EI (M) ⁺]
B148	N-[2-(3,5-Bis-trifluoromethyl-phenyl)-ethyl]-N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-benzamide	627.2 [EI (M) ⁺]
B149	6-Chloro-4-trifluoromethyl-pyridine-2-carboxylic acid	543 [ISP (M+H) ⁺]

	(4-tert-butyl-benzyl)-[2-(3-trifluoromethyl-phenyl)-ethyl]-amide	
B150	6-Chloro-4-trifluoromethyl-pyridine-2-carboxylic acid (4-tert-butyl-benzyl)-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-amide	561.2 [ISP (M+H) ⁺]
B151	6-Chloro-4-trifluoromethyl-pyridine-2-carboxylic acid (4-tert-butyl-benzyl)-[2-(3,4-dichloro-phenyl)-ethyl]-amide	543.1 [ISP (M+H) ⁺]
B152	6-Chloro-4-trifluoromethyl-pyridine-2-carboxylic acid (4-tert-butyl-benzyl)-[2-(3-fluoro-4-trifluoromethyl-phenyl)-ethyl]-amide	561.2 [ISP (M+H) ⁺]
B153	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-cyclopropyl-4-fluoro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	550.3 [ISP (M+H) ⁺]
B154	6-Methyl-2-trifluoromethyl-pyrimidine-4-carboxylic acid (4-tert-butyl-benzyl)-[2-(3-trifluoromethyl-phenyl)-ethyl]-amide	524.4 [ISP (M+H) ⁺]
B155	N-Butyl-N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-benzamide	444.4 [ISP (M+H) ⁺]
B156	N-Butyl-N-(4-tert-butyl-benzyl)-3-fluoro-5-trifluoromethyl-benzamide	409.2 [EI (M) ⁺]
B157	N-Butyl-N-(4-tert-butyl-benzyl)-2-fluoro-5-trifluoromethyl-benzamide	410.5 [ISP (M+H) ⁺]
B158	N-(4-tert-Butyl-benzyl)-2,3,5-trichloro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	542.0 [ISP (M+H) ⁺]
B159	N-(4-tert-Butyl-benzyl)-2,3,5-trichloro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-benzamide	561.9 [ISP (M+H) ⁺]
B160	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-chloro-4-fluoro-phenyl)-ethyl]-5-trifluoromethyl-benzamide	526.1 [ISP (M+H) ⁺]
B161	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-chloro-4-fluoro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	544.2 [ISP (M+H) ⁺]
B162	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-3-fluoro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-	544.3 [ISP (M+H) ⁺]

	benzamide	
B163	N-[2-(3-Bromo-phenyl)-ethyl]-N-(4-tert-butyl-benzyl)-3-chloro-5-trifluoromethyl-benzamide	554.1 [ISP (M+H) ⁺]
B164	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(3-ethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	520.4 [ISP (M+H) ⁺]
B165	N-(4-tert-Butylbenzyl)-3-chloro-N-[2-(3-cyclopropyl-4-fluorophenyl)-ethyl]-5-trifluoromethyl-benzamide	532.3 [ISP (M+H) ⁺]
B166	N-(4-tert-Butylbenzyl)-3-chloro-N-[2-(3,4-dicyclopropylphenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	572.3 [ISP (M+H) ⁺]
B167	N-(4-tert-Butylbenzyl)-3-chloro-N-[2-(4-chloro-3-cyclopropylphenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	566.2 [ISP (M+H) ⁺]
B168	N-(4-tert-Butylbenzyl)-3-chloro-N-[2-(4-chloro-3-isopropylphenyl)-ethyl]-5-trifluoromethyl-benzamide	550.4 [ISP (M+H) ⁺]
B169	N-(4-tert-Butylbenzyl)-3-chloro-N-[2-(4-chloro-3-isopropylphenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	568.2 [ISP (M+H) ⁺]
B170	N-(4-tert-Butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-N-[3-(3-trifluoromethyl-phenyl)-propyl]-benzamide	574.4 [ISP (M+H) ⁺]

B171	N-(4-tert-Butyl-benzyl)-3-chloro-N-[2-(4-chloro-3-ethyl-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide	554.3 [ISP (M+H) ⁺]
B172	N-(4-tert-Butyl-benzyl)-3-chloro-N-[3-(3-chloro-phenyl)-propyl]-2-fluoro-5-trifluoromethyl-benzamide	540.3 [ISP (M+H) ⁺]
B173	N-(4-tert-Butyl-benzyl)-3-chloro-N-[3-(3-chloro-phenyl)-propyl]-5-trifluoromethyl-benzamide	522.2 [ISP (M+H) ⁺]
B174	N-(4-tert-Butyl-benzyl)-3-chloro-N-[3-(4-chloro-phenyl)-propyl]-2-fluoro-5-trifluoromethyl-benzamide	540.3 [ISP (M+H) ⁺]

B175	N-(4-tert-Butyl-benzyl)-3-chloro-N-[3-(4-chloro-phenyl)-propyl]-5-trifluoromethyl-benzamide	522.2 [ISP (M+H) ⁺]
B176	3-Bromo-N-(4-tert-butyl-benzyl)-5-chloro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide	552 [ISP (M+H) ⁺]
B177	3-Bromo-N-(4-tert-butyl-benzyl)-5-chloro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-benzamide	570.3 [ISP (M+H) ⁺]
B178	N-[2-(3-Bromo-4-fluoro-phenyl)-ethyl]-N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-benzamide	590.3 [ISP (M+H) ⁺]

Example 2: N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-N-[2-(3-hydroxy-phenyl)-ethyl]-5-trifluoromethyl-benzamide

a) Preparation of N-[2-(3-benzyloxy-phenyl)-ethyl]-N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-benzamide:

The title compound was prepared in analogy to Example 1, using [2-(3-benzyloxy-phenyl)-ethyl]-(4-tert-butyl-benzyl)-amine (S9-C43) and 3-chloro-2-fluoro-5-(trifluoromethyl)-benzoic acid. MS: 597.3 [ISP (M+H)⁺].

b) Preparation of N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-N-[2-(3-hydroxy-phenyl)-ethyl]-5-trifluoromethyl-benzamide:

A solution of 1.1 g of N-[2-(3-benzyloxy-phenyl)-ethyl]-N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-benzamide (1.84 mmol) in 50 ml ethyl acetate was hydrogenated over 0.33 g Pd/C-5%. After completion of the reaction the suspension was filtered off and concentrated in vacuo to give 0.75 g of a colorless amorphous material. MS: 508.4 [ISP (M+H)⁺].

Example 3: N-(4-tert-butyl-benzyl)-3-chloro-5-ethyl-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-benzamide

285 mg of 3-bromo-N-(4-tert-butyl-benzyl)-5-chloro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-benzamide (0.6 mmol, Example B177), 44 mg of ethylboronic acid (1.75 mmol), 371 mg of tri-potassiumphosphate (0.05 mmol), 14 mg of tricyclohexylphosphine and 6 mg of palladium acetate were suspended in 2.3 ml toluene and 0.1 ml water and stirred at 100°C for 3.5 h under nitrogen. The reaction mixture was then cooled down to RT, diluted with 4 ml water and extracted twice with ethylacetate. The combined organic

layers were washed with brine, dried over magnesium sulfate, filtered off and concentrated under vacuo. The resulting residue was purified by flash column chromatography (Heptane / AcOEt: 95/5) to yield 192 mg of a yellow solid. MS (ISP) 520.3 (M+H)⁺.

5 Example 3-b: N-(4-tert-butyl-benzyl)-3-chloro-5-ethyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide

The title compound was prepared in analogy to Example 3, using 3-bromo-N-(4-tert-butyl-benzyl)-5-chloro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide (Example B176). MS (ISP) 502.3 (M+H)⁺.

10 Example 3-c: N-(4-tert-butyl-benzyl)-3-ethyl-2-fluoro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide

The title compound was prepared in analogy to example 3, using N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide (Example B63). MS (ISP) 572.3 (M+H)⁺.

15 Example 3-d: N-(4-tert-butyl-benzyl)-2-fluoro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide

The title compound was prepared in analogy to example 3, using N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide (Example B63). 544.2 [ISP (M+H)⁺]

20 Example 3-e: N-(4-tert-butyl-benzyl)-3-chloro-5-propyl-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide

The title compound was prepared in analogy to example 3, using 3-bromo-N-(4-tert-butyl-benzyl)-5-chloro-N-[2-(3-trifluoromethyl-phenyl)-ethyl]-benzamide (Example B176) and n-propylboronic acid. 516.2 [ISP (M+H)⁺]

25 Example 3-f: N-(4-tert-butyl-benzyl)-3-chloro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-5-propyl-benzamide

The title compound was prepared in analogy to example 3, using 3-bromo-N-(4-tert-butyl-benzyl)-5-chloro-N-[2-(3-fluoro-5-trifluoromethyl-phenyl)-ethyl]-benzamide (Example B177) and n-propylboronic acid. 534.3 [ISP (M+H)⁺]

Example 3-g: N-(4-tert-butyl-benzyl)-3-chloro-N-[2-(3-ethyl-4-fluoro-phenyl)-ethyl]-2-fluoro-5-trifluoromethyl-benzamide

The title compound was prepared in analogy to example 3, using N-[2-(3-bromo-4-fluoro-phenyl)-ethyl]-N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-benzamide
5 (Example B178) and ethylboronic acid. 538.3 [ISP (M+H)⁺]

Example 3-h: N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-N-[2-(4-fluoro-3-propyl-phenyl)-ethyl]-5-trifluoromethyl-benzamide

The title compound was prepared in analogy to example 3, using N-[2-(3-bromo-4-fluoro-phenyl)-ethyl]-N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-benzamide
10 (Example B178) and n-propylboronic acid. 552.2 [ISP (M+H)⁺]

Example 4: N-(4-tert-butyl-benzyl)-N-[2-(3-tert-butyl-4-hydroxy-phenyl)-ethyl]-3-chloro-2-fluoro-5-trifluoromethyl-benzamide

a) Preparation of N-[2-(4-benzyloxy-3-tert-butyl-phenyl)-ethyl]-N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-benzamide:

15 The title compound was prepared in analogy to Example 1, using [2-(4-benzyloxy-3-tert-butyl-phenyl)-ethyl]-(4-tert-butyl-benzyl)-amine (S9-C48) and 3-chloro-2-fluoro-5-(trifluoromethyl)benzoic acid. MS: 654.4 [ISP (M+H)⁺].

b) Preparation of N-(4-tert-butyl-benzyl)-N-[2-(3-tert-butyl-4-hydroxy-phenyl)-ethyl]-3-chloro-2-fluoro-5-trifluoromethyl-benzamide:

20 A solution of 182 mg of N-[2-(4-benzyloxy-3-tert-butyl-phenyl)-ethyl]-N-(4-tert-butyl-benzyl)-3-chloro-2-fluoro-5-trifluoromethyl-benzamide (0.278 mmol) in 15 ml ethyl acetate were hydrogenated over 100 mg Pd/C-5%. After completion of the reaction the suspension was filtered off and concentrated in vacuo. The resulting residue was purified by flash column chromatography (Heptane / AcOEt: 90/10) to yield 130 mg of a colourless
25 viscous oil. MS (ISP) 564 (M+H)⁺.

The compounds of formula I are cholesteryl ester transfer protein (CETP) inhibitors.

Atherosclerosis and its associated coronary heart disease is the leading cause of death in the industrialized world. Risk for development of coronary heart disease has been shown to be strongly correlated with certain plasma lipid levels. Lipids are transported in the blood by
30 lipoproteins. The general structure of lipoproteins is a core of neutral lipids (triglyceride and cholesterol ester) and an envelope of polar lipids (phospholipids and non esterified

cholesterol). There are three different classes of plasma lipoproteins with different core lipid content: the low density lipoprotein (LDL) which is cholesteryl ester (CE) rich; high density lipoprotein (HDL) which is also cholesteryl ester (CE) rich; and the very low density lipoprotein (VLDL) which is triglyceride (TG) rich. The different lipoproteins can
5 be separated based on their different flotation density or size.

High LDL-cholesterol (LDL-C) and triglyceride levels are positively correlated, while high levels of HDL-cholesterol (HDL-C) are negatively correlated with the risk for developing cardiovascular diseases.

Plasma lipoprotein metabolism can be described as a flux of cholesterol between liver and
10 the other tissues. The LDL pathway corresponds to the secretion of VLDL from the liver to deliver cholesterol by LDL to tissues. Any alteration in LDL catabolism could lead to up-take of excess cholesterol in the vessel wall forming foam cells and atherosclerosis. The opposite pathway is the mobilization of free cholesterol from peripheral tissues by HDL to deliver cholesterol to the liver to be eventually excreted with bile. In humans a significant
15 part of cholesteryl ester (CE) is transferred from HDL to the VLDL, LDL pathway. This transfer is mediated by a 70,000 dalton plasma glycoprotein, the cholesteryl ester transfer protein (CETP).

Mutations in the CETP gene associated with CETP deficiency are characterized by high HDL-cholesterol levels (>60 mg/dL) and reduced cardiovascular risk. Such findings are
20 consistent with studies of pharmacologically mediated inhibition of CETP in the rabbit, which argue strongly in favor of CETP inhibition as a valid therapeutic approach [Le Goff et al., Pharmacology & Therapeutics 101:17-38 (2004); Okamoto et al., Nature 406:203-207 (2000)].

No wholly satisfactory HDL-elevating therapies exist. Niacin can significantly increase
25 HDL, but has serious toleration issues which reduce compliance. Fibrates and the HMG CoA reductase inhibitors raise HDL-cholesterol only modestly (-10-12%). As a result, there is a significant unmet medical need for a well tolerated agent which can significantly elevate plasma HDL levels. The net result of CETP activity is a lowering of HDL-C and an increase in LDL-C. This effect on lipoprotein profile is believed to be pro-atherogenic,
30 especially in subjects whose lipid profile constitutes an increased risk for coronary heart disease. Therefore by inhibiting CETP activity there is the potential to inverse this relationship towards a lower risk and ultimately to protect against coronary heart diseases and associated mortality.

Thus, CETP inhibitors are useful as medicaments for the treatment and/or prophylaxis of atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbeta-lipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia.

In addition, CETP inhibitors may be used in combination with another compound, said compound being an HMG-CoA reductase inhibitor, a microsomal triglyceride transfer protein (MTP)/ApoB secretion inhibitor, a PPAR activator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant.

As described above, the compounds of formula I of the present invention can be used as medicaments for the treatment and/or prophylaxis of diseases which are mediated by CETP. Examples of such diseases are atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia. The use as medicament for the treatment and/or prevention of dyslipidemia is preferred.

The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.

Further, the invention relates to compounds as defined above for use as therapeutically active substances, particularly as therapeutic active substances for the treatment and/or prophylaxis of diseases which are mediated by CETP. Examples of such diseases are atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia.

In another embodiment, the invention relates to a method for the treatment and/or prophylaxis of diseases which are mediated by CETP. Examples of such diseases are atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypo-

- alphanlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia. A method for the treatment and/or prophylaxis of dyslipidemia is preferred.

- The invention further relates to the use of compounds of formula I as defined above for the treatment and/or prophylaxis of diseases are mediated by CETP. Examples of such diseases are atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphanlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia. The use of compounds of formula I as defined above for the treatment and/or prophylaxis of dyslipidemia is preferred.

- In addition, the invention relates to the use of compounds of formula I as defined above for the preparation of medicaments for the treatment and/or prophylaxis of diseases are mediated by CETP. Examples of such diseases are atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphanlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia. The use of compounds of formula I as defined above for the preparation of medicaments for the treatment and/or prophylaxis of dyslipidemia is preferred.

- In addition, CETP inhibitors are useful in combination with another compound, said compound being an HMG-CoA reductase inhibitor, an microsomal triglyceride transfer protein (MTP)/ApoB secretion inhibitor, a PPAR activator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant.

- The invention therefore also relates to pharmaceutical compositions comprising a compound of formula I as defined above in combination with an HMG-CoA reductase inhibitor, an microsomal triglyceride transfer protein (MTP)/ApoB secretion inhibitor, a PPAR activator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT inhi-

bitor or a bile acid sequestrant, as well as a pharmaceutically acceptable carrier and/or adjuvant.

The invention further relates to the use of compounds of formula I as defined above in combination with an HMG-CoA reductase inhibitor, a microsomal triglyceride transfer protein (MTP)/ApoB secretion inhibitor, a PPAR activator, a bile acid reuptake inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor, a fibrate, niacin, an ion-exchange resin, an antioxidant, an ACAT inhibitor or a bile acid sequestrant for the treatment and/or prophylaxis of diseases such as atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetalipoproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, and vascular complications of diabetes, obesity or endotoxemia, as well as to the use of such a combination for the preparation of corresponding medications.

The compounds of formula I and their pharmaceutically acceptable salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are inhibitors of the cholesteryl ester transfer protein (CETP).

The following tests were carried out in order to determine the activity of the compounds of formula I.

Activity of CETP inhibitors was determined using a buffer assay system. Partially purified CETP transferred radiolabeled cholesteryl ester from HDL donor particles to biotin-labeled LDL acceptor particles. The reaction was stopped by addition of streptavidin-coupled scintillation proximity assay (SPA) beads. These beads captured the biotinylated acceptor particles and transferred radioactivity was measured. The assay system was purchased and performed according to manufacturer's recommendations (Amersham Biosciences). Inhibitory activity of compounds was determined as percentage of positive control activity containing CETP together with donor and acceptor particles. Serial dilution of compounds was performed in order to determine the IC_{50} values.

Activity of the compounds was subsequently measured in the presence of plasma using the same assay as described above except that the source of CETP was human lipoprotein-deprived serum (LPDS). Inhibitory activity of compounds was determined as percentage of

positive control activity containing all the assay components except compound. Serial dilution of compounds was performed in order to determine the IC₅₀ values.

Under the latter assay conditions, the compounds of the present invention exhibit IC₅₀ values within the range of about 1 nM to about 100 μ M, e.g., of about 1 nM to about 1 μ M, e.g., of about 1 nM to about 200 nM. The following table shows measured values for some selected compounds of the present invention.

	IC ₅₀ (nM)
Compound B3	66848
Compound B104	1248
Compound B108	409

In vivo activity of the compounds of formula I were determined in hamster using the following protocol:

- 10 Male golden Syrian hamsters (6-week-old, 100-130 g) under standard chow diet received compounds in the morning by oral gavage using appropriate vehicle, blood was taken 2 h later by retro-orbital bleeding under isofluran anaesthesia and 7 h later on sacrificed animals. Plasma was separated from blood using low speed centrifugation and CETP activity was measured in plasma using the radioactive CETP activity assay as described above
- 15 except that diluted plasma replaced LPDS. *In vivo* CETP inhibition was expressed as CETP activity remaining in the plasma of treated animals as compared to plasma CETP activity of placebo treated animals.

- Efficacy of compounds in modulating plasma lipid levels can be determined in hamsters after 7 days of daily administration of compounds. Male hamsters are acclimated for 3-4
- 20 days to receive food as a paste made of 10 g chow and 10 g water per day. Compounds are then mixed within this paste and a portion containing the proper amount of compounds is given every morning for 7 days. Alternatively compounds can be given by oral gavage using the proper vehicle. Blood is taken before compound treatment by retro-orbital bleeding and at the end of the treatment on sacrificed animals. Plasma is separated from blood by
- 25 low speed centrifugation and selected organs are taken (e.g liver, fat, brain, etc.). Effects of compounds on plasma lipid levels are determined by measuring total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride using colorimetric enzymatic assays (Roche Diagnostic GmbH, Mannheim, Germany). HDL-C, LDL-C and VLDL-C are e.g., quanti-

fied using size exclusion chromatography on superpose-6 column using SMART™ system (Pharmacia). Lipoprotein distribution is calculated assuming a Gaussian distribution for each peak, using a non-linear, least-squares curve-fitting procedure to calculate the area under the curve. Plasma samples are also used to quantify CETP activity as described
5 above. Compound concentration is also determined in plasma and selected tissues as liver, fat, heart, muscle and brain.

Efficacy of compounds in modulating plasma lipid levels was also determined in cholesterol/fat fed hamsters. The protocol is identical as described above except that animals are fed with chow diet enriched with 10 % (w/w) saturated fat and 0.05 % (w/w) cholesterol.
10 Animals received this high fat diet 2 weeks before starting compound administration and continued this diet throughout the study. The 2 weeks pre-treatment induced an increase in plasma cholesterol and triglyceride levels allowing a better assessment of LDL-C and triglyceride lowering.

Efficacy of compounds in its ability to acutely raise HDL-C can be assessed in cynomolgus
15 monkeys. Animals are fed with standard primate maintenance diet. Compounds are formulated with appropriate vehicle and administered to animals by oral gavage. Blood is taken before and at several time-points after compound administration (usually 30 min, 1 h, 2 h, 4 h, 7 h and 24 h). Plasma is separated from blood by low speed centrifugation and CETP activity and plasma lipids are quantified. Compound potency and efficacy can be
20 assessed by measuring the HDL-C increase after this single-dose administration. In such pharmacodynamic model the extent together with the kinetics of the pharmacologic effect can be assessed.

The compounds of formula I and their pharmaceutically acceptable salts and esters can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parente-
25 ral or topical administration. They can be administered, e.g., perorally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils.

30 The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and their pharmaceutically acceptable, into a galenical administration form to-

gether with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, e.g., lactose, corn starch or derivatives thereof, talc, stearic acid or its salts
5 can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, e.g., vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, e.g., water, polyols, sucrose, invert
10 sugar and the like. Suitable carrier materials for injection solutions are, e.g., water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, e.g., natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene
15 glycols and cellulose derivatives.

Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.

20 The dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 mg to about 1000 mg, especially about 1 mg to about 100 mg, comes into consideration. Depending on the dosage it is convenient to administer the daily dosage in several dosage units.
25

The pharmaceutical preparations conveniently contain about 0.1-500 mg, e.g., 0.5-100 mg, of a compound of formula I.

The following examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.

30 Example A: Film coated tablets

<u>Ingredients</u>	<u>Per tablet</u>	
Kernel:		
Compound of formula (I)	10.0 mg	200.0 mg
Microcrystalline cellulose	23.5 mg	43.5 mg
Lactose hydrous	60.0 mg	70.0 mg
Povidone K30	12.5 mg	15.0 mg
Sodium starch glycolate	12.5 mg	17.0 mg
Magnesium stearate	1.5 mg	4.5 mg
(Kernel Weight)	120.0 mg	350.0 mg
Film Coat:		
Hydroxypropyl methyl cellulose	3.5 mg	7.0 mg
Polyethylene glycol 6000	0.8 mg	1.6 mg
Talc	1.3 mg	2.6 mg
Iron oxide (yellow)	0.8 mg	1.6 mg
Titanium dioxide	0.8 mg	1.6 mg

- The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magnesium stearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.

Example B: Capsules

<u>Ingredients</u>	<u>Per capsule</u>
Compound of formula (I)	25.0 mg
Lactose	150.0 mg
Maize starch	20.0 mg
Talc	5.0 mg

The components are sieved and mixed and filled into capsules of size 2.

10 Example C: Injection solutions

Compound of formula (I)	3.0 mg
Gelatin	150.0 mg

- 66 -

Phenol	4.7 mg
Sodium carbonate	to obtain a final pH of 7
Water for injection solutions	ad 1.0 ml

Example D: Soft gelatin capsules


Capsule contents	
Compound of formula (I)	5.0 mg
Yellow wax	8.0 mg
Hydrogenated Soya bean oil	8.0 mg
Partially hydrogenated plant oils	34.0 mg
Soya bean oil	110.0 mg
Weight of capsule contents	165.0 mg
Gelatin capsule	
Gelatin	75.0 mg
Glycerol 85 %	32.0 mg
Karion 83	8.0 mg (dry matter)
Titanium dioxide	0.4 mg
Iron oxide yellow	1.1 mg

The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules

5 are treated according to the usual procedures.


Claims

1. A compound of formula I



wherein

- 5 R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl;
 R^2 is hydrogen or a group



wherein

- 10 R^6 and R^7 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
 R^8 and R^9 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
 X is CR^{12} or N;
 Y is CH or N;
 15 wherein X and Y are not N at the same time;
 R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
 R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
 20 R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;
 A is CR^{10} or N;
 B is CR^{11} or N;
 25 D is CR^3 or N;

wherein $-B=A-$ and $-A=D-$ are not $-N=N-$;

R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;

R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;

wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;

and

n is 1, 2 or 3;

and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1 wherein R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl.

3. The compound according to claim 1 wherein R^2 is a group (a).


4. The compound according to claim 1 wherein R^2 is a group (b).

5. The compound according to claim 1 wherein

R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl;


R^2 is hydrogen or a group

20



(a)

or



(b)

wherein

R^6 and R^7 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^8 and R^9 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;


X is CR^{12} or N;

Y is CH or N;

wherein X and Y are not N at the same time;


- R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
- R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
- 5 R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;
- A is CR^{10} ;
- B is CR^{11} or N;
- D is CR^3 or N;
- 10 R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
- R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;
- R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;
- 15 wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;
- and
- n is 1, 2 or 3;
- and pharmaceutically acceptable salts thereof.

- 20 6. The compound according to claim 1 wherein
- R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl;
- R^2 is hydrogen or a group



(a)

or



(b)

- 25 wherein
- R^6 and R^7 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
- R^8 and R^9 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
- 30 X is CR^{12} or N;
- Y is CH or N;

wherein X and Y are not N at the same time;

R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

5 R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 and R^{11} is not hydrogen;

A is N;

B is CR^{11} ;

10 D is CR^3 ;

R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;

15 wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;

and


n is 1, 2 or 3;

and pharmaceutically acceptable salts thereof.

7. The compound according to claim 1 wherein

20 R^1 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halo- C_1 - C_6 alkoxy, C_3 - C_8 cycloalkyl, halo- C_3 - C_8 cycloalkyl or tri- C_1 - C_6 alkylsilyl;

R^2 is hydrogen or a group



wherein

25 R^6 and R^7 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

R^8 and R^9 are independently hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;

X is CR^{12} or N;

30 Y is CH or N;


wherein X and Y are not N at the same time;

- R^{12} is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
- R^5 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
- 5 R^4 is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy when at least one of R^3 , R^5 , R^{10} and R^{11} is not hydrogen;
- A is CR^{10} ;
- B is CR^{11} or N;
- D is CR^3 ;
- 10 R^3 is hydrogen, C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy;
- R^{10} is hydrogen, or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least one of R^3 , R^4 , R^5 and R^{11} is not hydrogen;
- R^{11} is hydrogen or is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl, OH or halo- C_1 - C_6 alkoxy, when at least two of R^3 , R^4 , R^5 and R^{10} are not hydrogen;
- 15 wherein at least two of R^3 , R^4 , R^5 , R^{10} and R^{11} are not hydrogen;
- and
- n is 1, 2 or 3;
- and pharmaceutically acceptable salts thereof.

- 20 8. The compound according to claim 1 wherein

R^1 is C_1 - C_6 alkyl;

R^2 is a group



(b)

- wherein
- 25 R^8 and R^9 are independently hydrogen, halo- C_1 - C_6 alkyl, halogen, C_3 - C_8 cycloalkyl or halo- C_1 - C_6 alkoxy;
- X is CR^{12} ;
- Y is CH;
- R^{12} is hydrogen, halogen or C_3 - C_8 cycloalkyl;
- 30 R^5 is hydrogen or halogen;
- R^4 is C_1 - C_6 alkyl, halo- C_1 - C_6 alkyl or halogen;
- A is CR^{10} ;


- B is CR¹¹ or N;
 D is CR³;
 R³ is hydrogen;
 R¹⁰ is halo-C₁-C₆alkyl or halogen;
 5 R¹¹ is hydrogen;
 and
 n is 1, 2 or 3;
 and pharmaceutically acceptable salts thereof.

9. A process for the production of a compound of formula I according to claim 1 which
 10 process comprises reacting an acid derivative, a compound of formula II



wherein R⁴, R⁵, A, B and D have the meanings as defined in claim 1 and W is hydroxy, OLi, ONa, OK or halogen,

with a secondary amine derivative, a compound of formula III



wherein R¹, R² and n have the meanings as defined in claim 1 and optionally converting the resulting compound into a pharmaceutically acceptable salt.

10. Pharmaceutical compositions comprising a compound according to any one of claims 1 to 8 as well as a pharmaceutically acceptable carrier and/or adjuvant.
 20 11. Pharmaceutical compositions according to claim 10 for the treatment and/or prophylaxis of diseases which are mediated by CETP.
 12. Compounds according to any one of claims 1 to 8 for use as therapeutically active substances.
 13. Compounds according to any one of claims 1 to 8 for use as therapeutically active
 25 substances for the treatment and/or prophylaxis of diseases which are mediated by CETP.

14. The use of compounds according to any one of claims 1 to 8 for the preparation of a medicament for the treatment and/or prophylaxis of diseases which are mediated by CETP.